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ABSTRACT
Antibiotic-resistant pathogenic microorganisms (such as MRSA and alike) represent a real and
significant threat to the health and wellbeing of the general population. The search for new
compounds of non-antibiotic nature that act as antimicrobial agents is an important task with
obvious practical applications in the biomedical field. Metal-based coordination and
organometallic compounds that demonstrate antimicrobial activity was found to exhibit a
completely different mode of action compared to antibiotics. That suggests the absence of the
mechanism of developing tolerance to these types of compounds at least for 30 - 40 years. Thus,
there are numerous organotin (IV), silver (I), copper (II) and arsenic (III) compounds that have
been extensively studied with that goal in the past. However, most of them are toxic to biological
species. On the contrary, organoantimony (III, V) compounds possess much lower general
toxicity but demonstrate appreciable antimicrobial properties and better body clearance.
Unfortunately, there is still an insufficient amount of information regarding the latter class of
compounds. Our research group’s previous experience clearly identified cyanoximes –
compounds with the general formula NC-C(=NOH)-R, with R being an electron-withdrawing
group – as potent biologically active compounds. These small molecules also act as very good
ligands binding a variety of metal ions and metalloids with many compounds showing a good
potential for biomedical applications. Except for one publication in 2000, there are no
investigations of any kind of Sb-based compounds with oxime-bearing ligands. Therefore, the
goal of the proposed research is to synthesize and characterize a series of antimony complexes
with some specifically selected biologically active cyanoximes structures. All the synthesized
novel compounds were characterized by elemental analysis (C,H,N), IR & NMR spectroscopy,
thermal analysis (TG/DSC), and x-ray crystallography. The biological activity of the synthesized
compounds was tested against bacterial strains MRSA, PAO1, and E. coli. Optical density (OD)
was used to measure microbial cell growth, at a wavelength of 600 nm (OD600).
KEYWORDS: cyanoximates, MRSA, biologically active, organoantimony, cytotoxicity,
toxicity, antimicrobial activity, cell growth, thermal analysis, diastereomers.
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I. INTRODUCTION
I. 1. Antimicrobials
Antimicrobial compounds are one of the most important drugs in modern medicine
because they are used to treat numerous infections. There is a distinction between antibiotics and
antimicrobials: Antibiotics have an effect only on bacteria, while antimicrobial reagents affect all
microorganisms including bacteria, fungi, and viruses. Antimicrobials have a very large impact
on the treatment of infectious diseases amongst other classes of drugs used in medicine.
Although most of our exposure to antimicrobials is attributed to the 1900s with the emergence of
the modern era of antibiotics, traces of tetracycline – an antibiotic – found in the human skeletal
remains from ancient Sudanese Nubia dating back to 305-550 CE suggest that some were
already in use.1 Paul Ehrlich is known widely as the father of antimicrobial chemotherapy and
bioinorganic chemistry because with the help of his Japanese assistant Sahachiro Hata, they
were able to find the “magic bullet” (compound 606) capable of treating infectious microbes
without also killing the host.2 This compound is an arsenic-based chemical (C 12 H13 As2 ClN 2O2 ),
was used to successfully treat syphilis and was later marketed as Salvarsan, meaning
“Lifesaving”. Ehrlich designed methods in search of this effective compound, and such strategy
is currently still being used.1
The accidental discovery of Penicillin in 1928 by Alexander Fleming is the first of many
natural antibiotics found by scientists. Penicillin was monumental around the time of its
discovery as it was effective against streptococci, meningococci, and Corynebacterium
diphtheriae, the causative agent of diphtheria. 3,4,5 Thus, increasing the life expectancy and
reducing the mortality rate. A few years later, German scientists Josef Klarer, Fritz Mietzsch, and
Gerhard Domagk discovered antibacterial activity of a synthetic dye, prontosil which is a

1

sulfanilamide drug. Sulfanilamide became the first synthetic antimicrobial drug created and its
success led to the synthesis of a wide variety of other synthetic antimicrobials like quinolines
that do not occur in nature.5 Antibacterial drugs can either work by killing off the bacteria
(bactericidal) or reversibly inhibiting the growth of the bacteria (bacteriostatic). These drugs can
also be narrow-spectrum or broad-spectrum substances. Narrow-spectrum ones have specific
antimicrobial targets that they affect like only gram-positive bacteria, or gram-negative bacteria
while broad-spectrum drugs have a wide range of target, attacking microbes with no respect to
their value to the body.6 That is one of the issues with broad-spectrum antimicrobials as they also
attack normal healthy microbiota within the body that keeps some harmful microorganisms in
check. This increases the possibility of antimicrobial resistance to antimicrobial drugs. 7

I. 2. Antimicrobial Resistance
Antimicrobial resistance (AMR) occurs when microorganisms are not affected anymore
by the drugs designed to kill or arrest their growth. This is one of the greatest global public
health challenges we are currently facing. According to the Center for Disease Control and
Prevention’s (CDC) report on antibiotic/antimicrobial resistance conducted in 2019, annually,
there are more than 2.8 million antibiotic-resistant (AR) infectious cases of which more than
35,000 people die.8, 72 Aside that, the economic impacts due to treating these infections as well as
from the loss of productivity is astronomical – about $4.6 billion annually.9 With modern
medicine’s reliance on antimicrobials especially antibiotics in treating diseases such as
pneumonia, tuberculosis, sexually transmitted diseases. The problem with AR/AMR is that we
will have no effective treatment soon. The world is headed toward a very dangerous place where
minor infections could once again be detrimental. Various organizations like the World Health
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Organization (WHO), CDC and World Economic Forum have shown great concern and deemed
antibiotic resistance as a “global public health concern”. 10

I. 3. Causes of Antimicrobial Resistance
An overuse of antibiotics is one of the paramount reasons for the rapid evolution of
resistance within bacteria. Other causes include inappropriate prescribing which goes hand in
hand with the inability of patients to follow through with the full dose of the drug. Extensive use
of antibiotics in agricultural settings, as well as wide availability of few antibiotics are also
important factors causing the rapid increase in resistance to various antibiotics by bacteria. 4
Therefore, we now have a multiple-drug resistance (MDR) phenomenon.11 This situation led to
the appearance of antibiotic resistant bacterial infections such as Methicillin-Resistant
Staphylococcus Aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) which are
increasingly becoming difficult to treat with the current range of available antibiotics. 10, 11
Resistance can come by natural process, which is intrinsically present and always expressed in
the species or induced. That is when the resistance is present but expressed only when exposed to
antibiotics. Also, it can be acquired through transformation, transduction, or conjugation. 14 All
the aforementioned factors are selection pressures that fuel the rapid evolution of drug resistance
that would not have happened naturally that fast. Once the genes encoding antibiotic resistance
arises through various mutations in bacteria, they are exchanged among other bacteria. With
gene transfer through transformation, pieces of DNA are taken from the environment and
incorporated into the genome of the bacterium. With gene transfer through transduction,
bacteriophages containing the favorable AMR genes are used to infect other bacteria and with
conjugation, transfer of genes is done through mating with other bacteria. 10,12
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I. 4. Mechanism of Antimicrobial Drug Resistance
Antimicrobial drug resistant genes acquired by microbes can work by either modifying or
inactivating the drug, preventing cellular uptake, or increasing efflux pumps, drug target site
modifications and enzymatic bypass.10, 13
Drug Modification or Inactivation. With this mechanism, the genes acquired by the
microorganism encode for enzymes that can modify the antimicrobial compound making it
ineffective against their drug targets. These enzymes can transfer a chemical group onto the drug
which makes it usable for metabolism. Another mode of action is the degradation of the drug by
breaking down bonds within the drug molecule. This is seen in the activity of β-lactamases
hydrolyzing β-lactam bond within the β-lactam ring of drug molecules and inactivating them or
in the acetylation, phosphorylation and adenylation of aminoglycosides as a form of resistance
against these drugs.1,13,14
Increase of Efflux Pumps or Prevention of Cellular Drug Uptake. Naturally, the
composition of the bacterial cell wall makes it difficult of certain antimicrobials to penetrate and
affect the bacteria. This intrinsically provides resistance to bacteria that lack a cell wall against
drugs that target the cell wall.14 Some antimicrobial compounds are hydrophilic and larger in size
and, hence, need bigger porins to enter the cell. The mechanism here involves the modification
of the selectivity of these porins to prevent the uptake of these antimicrobials or reducing the
number of porins present within the cell walls and therefore increasing the resistance towards
those antimicrobials.13,14 An example is the carbapenem resistance in Pseudomonas aeruginosa
where the abundance of OprD porin, the main entry point of carbapenems, is decreased on the
outer membrane of the microbe.13 Another way to increase resistance is through the increase in
the abundance of efflux pumps that actively pump out the antimicrobial out of the cell,
preventing it from ever reaching the threshold dose required for an effect. This can be achieved
4

through the overexpression of genes encoding these transporters under certain environmental
stimuli such as the presence of antimicrobial compounds. 14 The presence of biofilms also
increased the expression of genes required for resistance. These genes can then be shared by cell
conjugation among the bacteria community14 and allows for cross-resistance against other
antimicrobials.
Drug Target Site Modification. Bacteria have a variety of target sites that
antimicrobials target and so the modification of these sites can render the antimicrobial
ineffective when administered. Some target sites where mutations were observed include
metabolic enzymes, DNA gyrases or topoisomerases, ribosomal subunits, lipopolysaccharide
(LPS) structures and peptidoglycan subunit peptide chains. 13,14 Streptococcus pneumoniae alters
the penicillin-binding-proteins’ (PBPs) active site (competitive binding) to prevent the binding of
β-lactam drugs, making it resistant to those drugs. 13 Staphylococcus aureus, widely known for its
resistance to methicillin, developed this through the acquisition of mecA gene responsible for
changing the structure of PBP2a and decreasing its affinity for PBPs and in effect inhibiting drug
binding.13,14 This provides resistance against β-lactam drugs as seen with Methicillin-resistant
Staphylococcus aureus (MRSA).

I. 5. Strategies for Discovery of New Antimicrobial Drugs
With the rampant global issue of AMR showing no signs of slowing down, there is a
need for some novelty to the drugs or targets they affect in bacteria. Pharmaceutical companies
are steering clear of research into antimicrobials15 because they do not get high returns on such
investments compared to development of drugs for most chronic, life-threatening non-infectious
diseases such as hypertension. Additionally, approval times by the Food and Drug
Administration (FDA) board is about 6.2 years, making it difficult to for researchers to work on
5

novel antimicrobials. Such problems could be remedied with the provision incentives to
pharmaceutical companies to encourage more research into antimicrobials. Strategies that have
been tried to remedy the issue of AMR include improvement of currently used antimicrobials, or
preventing and reducing dependence on antimicrobial1 because bacteria will develop resistance
naturally against antibiotics, but it is the rampant use of antibiotics that is ushering in the spread
of AMR across the globe.
With MDR microorganisms, synthetic antimicrobials may be the way out as specific
drugs can be synthesized to affect specific drug target sites. Elementorganic compounds like
organoarsenic and organotin have a great history in the search for antibiotics to treat various
diseases.1 While there is a plethora of information on arsenic, other inorganic compounds may
offer antimicrobial properties that have not yet been explored. Coordination compounds of silver
(I),16 mercury (I),17 copper (II)18 and zinc (II)19 have been studied and shown that only the silver
(I) complexes possess antimicrobial properties. 71 Henceforth, they have been used in colloidal
solutions for topical applications, coatings for various implants and as fabric for wound
treatment.20 - 22 With addition of a variety of organometallic complexes to research, the
possibility of finding novel antimicrobials is practically endless.

I. 6. Element of Choice: Antimony
Antimony is in the main Group 15 (pnictogens) in the periodic table along with Nitrogen,
Phosphorus, Arsenic and Bismuth. Antimony has atomic number 51, atomic weight 121.760
g/mol with melting point (m.p.) and boiling point (b.p.) of 630.63 °C and of 1,587 °C
respectively.30 The pnictogens display varying properties despite being in the same group.
Nitrogen and Phosphorus are non-metals, Arsenic and Antimony are metalloids, and Bismuth
demonstrates metallic properties. Antimony comes from the Greek words anti and monos,
6

meaning “enemy of solitude”, but its symbol (Sb) is derived from its Latin name, stibium. 68
Antimony has four oxidation states: -3, 0, +3 and +5, with the most common oxidation states
being +3 and +5 because of their stability. The H 3 SbO 3 and H 3 SbO 4 are acids corresponding to
those oxidation states. Sb is a poor conductor of heat and electricity.23, 30 Stibine (SbH 3 ) is a
gaseous antimony compound with an oxidation state of -3, and forms in reaction of acids on
metal Zn/Sb alloys through the reduction of antimony. Stibine is toxic and poses a danger since it
can be released when some lead batteries are overcharged because Pb is used in alloys with
Antimony.24

I. 7. Uses of Antimony
Antimony’s use can be dated back to the early Egyptians. It has been used as coatings for
other metals, or for cosmetic purposes – even as an eyeliner.25 Other uses of antimony are in
flame retardants, in semi-conductor devices, and in alloys for batteries and bullets. 26 In the
modern era, the biological aspect of antimony has been explored and applied. Main group
compounds like Arsenic and Bismuth in group 5 have wide pharmacological applications like
salvarsan being used back in the day for treating syphilis. Bismuth subsalicylate being the active
ingredient in Pepto-Bismol, is a very important drug of choice in many households for most
digestive issues like indigestion, heartburn, and diarrhoea.27, 69 Antimony derivatives or
organoantimony compounds have been used to treat diseases such as trypanosomiasis and
leishmaniasis because they exhibit appreciable effect as biocides, fungicides, antitumor and
antioxidants. 28
Medicinal uses. Antimony compound, NaSbO 3 - meta antimonate, has been used as an
emetic up until the late 1700s. A compound with tartaric acid and Sb (III), was used as a
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treatment drug for leishmaniasis, but had numerous side effects such as coughs and depression
and even death due to its high toxicity.29 One of the successful uses of antimony is in the
treatment of Leishmaniasis. Leishmaniasis is caused by a protozoan parasite of genus
Leishmania, transmitted through the bite of infected sandflies. This results in either cutaneous
leishmaniasis (CL) or visceral leishmaniasis (VL), with the latter being most severe. 29 The
spread of Leishmaniasis in South and Central America, Bangladesh, southern Europe, and North
Africa led to the reliance on organoantimonial compounds for drug therapy. Antimonials contain
this element in trivalent and pentavalent forms. Trivalent antimonials (those having Sb (III))
effectively killed parasitic cells, but unfortunately, eventually killed the human host too. This
fact initiated the discovery of pentavalent antimonials, which are less toxic than their trivalent
counterparts. Pentavalent antimonials (having Sb(V)) such as sodium antimony gluconate
(Pentostam)31 and meglumine antimonate (Glucantime)32 have been in use for more than six
decades to treat Leishmaniasis and Indian kala-azar disease.29, 70 Additionally, organoantimony
compounds have been studied to show antimicrobial, antifungal, and antitumor activity. 33-38, 70
The latter was seen in some diphenylorganoantimony (V) thiophosphates such as Ph 2 Sb{S2 PR2 }(Ph = C6 H5 , R = Ph, i-OC3 H 7 )39, 40 and methylantimony (III) complexes like (CH 3 )SbL
where L are derivatives of meta-substituted salicylic acid.41 Observed organoantimony’s
antitumor activity is similar in mechanism and effect to cisplatin with cytotoxicity levels lower
than that for Palladium (Pd) and Platinum (Pt). 27

I. 8. Mechanism of action of antimonials
Testing that has been done on amastigote cells showed that the pentavalent antimony
was taken up by the cell and reduced to the more active and toxic trivalent form which kills the
cell.42, 43 This reduction requires thiol compounds to provide the reducing power, higher pHs and
8

slightly elevated temperatures. The trivalent form on antimony in vivo targets zinc finger
containing proteins and trypanothione reductase (TR) in the leishmania parasite. 29 The TR
prevents the cells from damage by oxidative stress and toxic heavy metals. Zinc fingers are also
involved in DNA recognition, RNA packaging, transcriptional activation, regulation of
apoptosis, protein folding and assembly, and that the apoptosis of amastigotes is due to influx of
calcium ions and increased oxidative stress. 29, 43 This is the pro-drug mechanism of action model
(Figure 1) for the pentavalent antimonials. The other two proposed models are the intrinsic
antileishmanial activity and host immune activation model.29, 32 The intrinsic antileishmanial
activity model proposes that pentavalent antimonials do not have to be reduced to the trivalent
forms to exact an effect. Studies into this model were carried out on amastigotes has suggested
intrinsic antileishmanial activity is achieved through interruptions in the macromolecular
biosynthesis through inhibition of glycolysis and fatty acid β-oxidation. Finally, the host immune
activation model depicts that the action of the pentavalent antimonial is that of immune system
activation to not only clear the Leishmania parasites but also offer immunity against future
infections. 29 The prodrug model (Figure 1) is currently the most widely accepted mechanism. 44
Ulamina (an experimental drug containing antimony pentachloride and N-methyl-glucamine),
showed that when injected, only 23% of the pentavalent is reduced to trivalent antimony. 45
Studies with monkeys also supported the prodrug model in that when meglumine antimoniate
(Sb V) was administered, the amount of trivalent antimony in the plasma rose from 5% on day
one of exposure to about 50% on day nine.46
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I. 9. Toxicity of Antimony and its Excretion
Excretion of antimony from the body is reliant on the form of antimony (+3 or +5)
absorbed in the gastrointestinal tract. Pentavalent is excreted more rapidly than trivalent
antimony, with over 50% of pentavalent being excreted in urine within 6 hours after intravenous
administration compared to 25% of trivalent after 24 hours of administration. 23 Analysis of data
from treatment of patients suffering from Leishmaniasis with antimonials have shown the
primary targets of antimony are the heart, gastrointestinal tract, musculoskeletal system, liver,
pancreas, and the nervous system. Symptoms that manifest include dizziness, nausea, abdominal
pain, diarrhea, anorexia, and myalgia.

47-49

Figure 1. Prodrug model showing apoptosis inducing mechanism of antimony in vivo [reproduced
from Reference 29]
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I. 10. Coordination compounds
Coordination complexes of the Werner type are products of Lewis acid -base reactions
where neutral molecules or negatively charged ions (anions) – ligands – bind to a central atom,
normally a metallic ion or atom.51-53 The ligands are Lewis bases which contain at least one pair
of electrons to donate to the metal ion or atom, forming a dative covalent bond in which the base
donates both electrons for the formation of the bond. The metal atom or ion is the Lewis acid
which accepts the electrons from the Lewis base. The coordination number refers to ligands that
are classified as monodentate (binding to the metal ion or atom at one place and donating a pair
of electrons), or polydentate (binding to the metal ion or atom at more than one place). Some of
the ligands exists as ambidentate ligands, which contain two or more donor atoms and can bind
to the central metal atom or ion via either donor atom. Examples of such ligands are nitrite ions,
linear pseudohalide ions.53 The coordination number refers to the number of bases or donor
atoms, groups attached to the central metal atom or ion. There are bi- and polydentate ligands,
which bind tightly to metal ions with many of them being chelating agents used for separation of
and extracting metals.51 Numerous chelating organic compounds are used in treating metal
poisoning since they bind stronger to the metal ions than molecules in human tissue. 51 An
example is ethylenediaminetetraacetic acid (EDTA), or mercaptopropanol, HS-CH 2 -CH 2 -CH2OH. There are also naturally occurring powerful chelates and macrocycles containing metal ions
such as chlorophyll, hemoglobin, cyancobalamin, and others.54

I. 11. Cyanoximes: Ligands for Coordination Compounds
Cyanoximes are a new class of oximes that can form a variety of coordination
compounds. The general structure for cyanoximes is HO-N=C(CN)-R, where R represents the
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varying electron withdrawing group, typically O, N, or S (Figure 2). The nitrile group (CN)
makes the cyanoxime 10000 times more acidic and a better ligand when compared to other
oximes.55 It also makes it easier for deprotonation to happen in both aqueous and polar organic
solvents which yields a color change due to the transition from n→π* in the nitroso
chromophore.56-59 The linear and polar nitrile group provides rigidity to the cyanoximes which
helps in crystallization of both ligands and their metal complexes. 55 These cyanoximes are also
ampolydentate in nature as demonstrated by one of them, 2-oximino-2-cyanoacetamide, called
ACO - anion, demonstrating different modes of binding to various metals (Figure 5). Cyanoximes
also show rich coordination chemistry.55 For synthesis of cyanoxime three main routes exist
(Figure 7), with the general mechanism of formation of cyanoximes shown in Figure 3, along
with the two possible diastereomers - syn and anti. The process of diastereomers formation is
purely kinetic driven since thermodynamic of the oximination reaction is the same. Thus,
different groups attached to the >C=N-O fragment due to their varied bulkiness and electronic
structure are affecting the ratio of diastereomers. This was confirmed by X-ray analysis and
NMR spectroscopy The illustrations in Figures 3 and 4 also explain the possibility of the four
different experimentally found geometrical isomerism present within cyanoximes (Figure 6).
Figure 4 shows the delocalization of the negative charge in aryl-cyanoxime anions such as in Ag
(I), and Tl (I) salts. It is evident that the free rotation about the single bond (N-C) allows for the
O=N- fragment to rotate, forming two out of the three resonance forms possible within the
cyanoxime. There are 44 known cyanoximes today (Figure 8) that have been characterized thus
far with many found to have significant biological activity. It ranges from growth regulation,
detoxification, to antimicrobial applications. 60-67 Antimicrobial activity has been seen in silver (I)
cyanoximates and in compounds containing the sulfur thioamide-cyanoxime, HO-N=C(CN)
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C(S)NH 2, (later TCO)73, 74 Currently, there are new antiviral oxime-containing compounds being
developed that affect HIV, SARS-CoV-2, and MERS-CoV-2, all of which are now in different
stages of clinical trials.75
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Figure 2. Types of oximes and their precursors.
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N

cyanoximes

Figure 3. Mechanism of formation of two diastereomers – syn and anti – during synthesis of
cyanoximes.

In previous research carried out by my colleague Kevin Pinks, tetraphenyl antimony was
complexed with cyanoxime ligand to test for the presence of any antimicrobial activity. 60 The
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SbPh4 Br as initial compound is available commercially. The cyanoxime ligands were chosen for
their partial water solubility, polarity as well as earlier demonstrated biological activity.
Tetraphenyl antimony has considerable lipophilicity and hence was a good baseline to start in the
quest for new synthetic non-antibiotic antimicrobial compounds using the antimony
cyanoximates. The higher the lipophilicity of a compound, the better it binds to its proteins in
vivo and the greater its distribution.97 With the help of collaborative group in the Department of
Microbiology and Molecular Genetics at Oklahoma State University, Pinks tested his compounds
against bacterial strains -Methicillin-resistant Staphylococcus aureus strain NRS70, Escherichia
coli strain S17, and Pseudomonas aeruginosa strain PAO1 – and fungal strains – Candida
albicans, Cryptococcus neoformans. His research showed that, of the five antimony (V)
cyanoximates tested for antimicrobial activity, Sb(Ph)4 (ACO), and Sb(Ph)4 (ECO), had
significant antimicrobial effect against all three bacterial strains used: two gram-negative E. coli
strain S17 and P. aeruginosa strain PAO1, alongside a single gram-positive Methicillin-resistant
Staphylococcus aureus strain NRS70. The Sb(Ph)4 (TCO) and Sb(Ph)4 (TDCO), containing the
thioamides, had significant effects on the gram- positive MRSA strain NRS70 only. Antifungal
studies showed that Sb(Ph)4 (ECO) was effective against Cryptococcus neoformans and Candida
albicans in a positive trend. The Sb(Ph)4 (TCO) was the next contributor towards antifungal
activity against both strains. The Sb(Ph)4 (ACO) and Sb(Ph)4 (TDCO) were only effective at
inhibition of Cryptococcus neoformans, while those compounds did not contribute to any
inhibition towards Candida albicans. Finally, testing of free cyanoximes against both the
bacterial and fungal strains yielded no effect showing that they had to be complexed with
antimony for there to be an effect.60
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Figure 4. Schematic representation of delocalization of negative charge in aryl-cyanoxime anions
(such as in Ag, Tl-salts) showing that two out of three isomeric forms represent anions in the
nitroso form where the rotation of the O=N- fragment around N-C bond is possible.

Figure 5. Ampolydentate character of cyanoxime anions for ACO- anion. Binding modes enclosed
in boxes were confirmed by crystallographic studies.

16

Figure 6. Experimentally found geometrical isomers of cyanoximes. (X=O, S; R= alkyl, aryl
groups).
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Figure 7. Routes for cyanoxime synthesis.
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+ NaOPr
in n-PrOH
+ RO-N=O,
r.t., +N2

Figure 8. List of known cyanoxime ligands. * Compounds with determined crystal structures.
18

II. RESEARCH GOAL

My research goal was to prepare a series of new organoantimony (V) compounds and
characterize them. The ligands used were previously identified cyanoximes that had biological
activity.55 The choice of metalloid fragment was SbMe3 , with the source of antimony obtained
from lab-synthesized trimethylantimony dibromide (SbMe3 Br2 ). Compared to the previously
used tetraphenyl (V) antimony, trimethylantimony (V) is less lipophilic and bulky as well as
being able to bind two cyanoxime ligands instead of one. This increased overall solubility in
organic solvents, and cyanoxime “double” load is proposed to increase the antimicrobial effect
previously witnessed with the tetraphenyl (V) antimony cyanoximates obtained by Pinks. The
choice of anionic ligands for this research was disubstituted arylcyanoximes which have proven
biological activity.55 These will be novel antimony cyanoximates that will be tested for their
antimicrobial activity. For good comparison on the effect of decreased lipophilicity and
bulkiness, I synthesized antimony cyanoximates with the ligands used in previous research for
antimicrobial studies by Kevin Pinks (Figure 9).
Due to limited research on these compounds, I synthesized the antimony cyanoximates,
and submit them for testing on bacterial and fungal strains to assess for antimicrobial properties
at our collaborative institution – Department of Microbiology and Molecular Genetics at
Oklahoma State University. There are two research groups led by Professor Marianna
Patrauchan and Professor Karen Wozniak. The goal was to compare the effect of adding one
more cyanoxime moiety to the antimony complex as compared to Pinks’ molecules. My
hypothesis therefore will be that increasing the number of cyanoxime groups attached to the
Sb(V) center should increase its microbial properties compared to not having any cyanoximes
attached. My ligands of choice are shown in Figure 9 – which includes both the new aryl
19

cyanoximes and the old, tested cyanoximes that Kevin Pinks worked with. The new halogenated
aryl cyanoximes have already established biological activity.

20

Figure 9. Choice of ligands for antimicrobial studies.

* Indicate Ligands used by Kevin Pinks in his work.
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III. EXPERIMENTAL PART

III. 1. Reagents and General Considerations
Solvents used for carrying out reactions and crystallizations were HPLC grade and
employed without further purification. The inorganic compounds (Na metal, NaCl and Na 2 SO4
anhydrous) were obtained from Mallinckrodt. Reagent grade ethyl cyanoacetate (C 5 H7 NO2),
chloroform (CHCI 3 ), and Antimony (III) chloride (99.0%) were purchased from Sigma Aldrich
for my synthesis. All other chemicals and organic solvents - isopropyl alcohol (i-PrOH),
acetonitrile (CH 3 CN), diethyl ether sodium nitrite (NaNO₂), concentrated sulfuric acid (H₂SO4),
and concentrated hydrochloric acid (HCI) from Fisher Scientific. Cyanoximes and their silver (1)
derivatives selected for current studies were either taken from a bank of ligands in Dr.
Gerasimchuk's research laboratory or obtained using published procedures from starting
substituted acetonitriles.60,71,76,77,82 The arylcyanoximes were synthesized through the same
process. Therefore, compounds such as Ag(MCO), Ag(ACO) and Ag(ECO), were used for
syntheses of organoantimony(V) cyanoximates from previous investigations'. The thioamidesbased cyanoximes H(TCO), H(TDCO) as well as all TI(I) cyanoximates were prepared by Dr.
Gerasimchuk to avoid graduate students' exposure to stench or toxic chemical compounds.
Melting points were determined with the use of pre-calibrated apparatus with urea and
naphthalene standards Digi-Melt (MPA106 SRS) in open melting point capillaries and reported
without correction. Elemental analysis on C, H, N (and S with thioamide-based cyanoximes)
content was conducted at the Atlantic Microlab (Norcross, GA). Elemental analysis was not
conducted on compounds that had their crystal structures already determined since the crystal
structure confirms the elemental composition of the compound being studied.
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III. 2. Vibrational spectroscopy
The IR-spectra of all compounds reported herein were studied by using Bruker ATR FT
spectrophotometer. The resolution was set to be 4 cm-1 with 64 scans in the range of 400-4000
cm. An atmospheric compensation and baseline correction were applied for data treatment.

III. 3. NMR spectra
Some spectra were obtained on a Varian INova-400 MHz spectrometer at room
temperature in DMSO-d 6 and CDCl2 solutions for 1 H and 13 C, respectively. Spectra of
halogenated ligands and organoantimony (V) complexes were recorded at Northeastern
University, (NEU) in Boston, MA.

III. 4. X-ray crystallography
Suitable single crystals of organoantimony(V) cyanoximates were grown at +4 °C
exclusively using the vapor diffusion method: acetonitrile solutions of compounds were placed
into the inner tube and vapors of anhydrous ether were used as crystallizing agent from the outer
tube with a screw cap. Normally within 2-3 weeks after setting up, transparent, well-shaped
crystals appeared on the walls in the inner tube suitable for crystallographic studies. All crystals
selected for studies were placed on plastic MiTeGen holders attached to the copper-pin on the
goniometer head of the Bruker APEX-2 diffractometer, equipped with a SMART CCD area
detector. The intensity data were collected at low temperature. Data collection was done in ω
scan mode using the Mo tube (Kα radiation; λ = 0.71073 Å) with a highly oriented graphite
monochromator. Intensities were integrated from 4 series of 364 exposures, each covering 0.5 °
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steps in ω at 20 - 60 seconds of exposure time depending on the crystal diffracting power, with
the total data set being a sphere. The space group determination was done with the aid of the
XPREP software. The absorption correction was performed by a crystal face indexing procedure
with use of a video microscope followed by numerical input into the SADABS program. Both
cited programs are included in the Bruker AXS software package. All structures were solved by
direct methods and refined by least squares on weighted F² values for all reflections with I >
3Ϭ(I) using the SHELXTL program. In several structures it was possible to identify all H-atoms
on the electron density map due to the high quality of crystals. However, in some structures Hatoms were placed in calculated positions in accordance with the hybridization state of a hosting
carbon atom and were refined isotropically. No apparent problems or complications were
encountered during the structures’ solutions and refinement as evident from very positive
PLATON checkCIF reports. Values of selected bond lengths and valence angles are presented in
respective Tables following the discussion of crystal structures. A representative drawing of the
crystal structures and packing diagrams was done using the ORTEP 3v2 and Mercury software
packages. All determined crystal structures have been deposited at CCDC (England), with
PLATON checkCIF reports.

III. 5. Thermal stability studies
Thermal stability of the obtained metal complexes was assessed using Q-600 TG/DSC
analyzer (TA Instruments, Delaware, USA) under UHP Ar flow of 100 mL/min at 10 °/min heat
rate. Heating of samples was carried out to 800 °C at which the samples' complete
decomposition was attained.
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IV. PREPARATION OF COMPOUNDS
IV. 1. Synthesis of Initial Trimethylantimony (V) Dibromide (SbMe3 Br2 ), Metalloid Source
Due to the unavailability of trimethylantimony dibromide commercially, it was synthesized in
the lab. The reaction is shown in Figure 10. The procedure followed was that of G. O. Doak et.
al1 submitted in Inorganic Syntheses, Volume IX.78,79 Methylmagnesium iodide solution,
CH 3 MgI, 3 M in diethyl ether, was purchased from Sigma Aldrich; (#25,436-3). This allowed
for bypassing the initial reaction (1) in Figure 10. A dry ice/acetone bath was made in a Dewar.
With a syringe, 30 mL of the Grignard reagent (CH 3 MgI) was transferred into a 3-necked roundbottomed flask under Argon flow. A solution of 6.845 g of Antimony (III) chloride (SbCl3 ) in
17.7 mL ether was made and added dropwise to the flask via an addition funnel.

Figure 10. Synthesis of Trimethylantimony (V) Dibromide.
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With a mechanical stirrer to facilitate stirring, the reaction progressively turned grey. The stirrer
was disconnected once the reaction reached completion and a distillation apparatus was
connected to the reaction flask with the receiving flask chilled in an ice bath. A slurry white
mixture of trimethylstibine and ether was collected in the receiving flask and brominated with a
solution of 0.5 mL bromine in 7.8 mL carbon tetrachloride (CCl4 ). The product turned a
consistent yellow color and was dried overnight. The crude product was recrystallized in hot
ethanol into a white crystalline product. The yield of the purified product was 1. 152 g to 1.763 g
(23% to 35%) based upon SbCl3 . The melting point was 183.2 – 183.5 °C. IR spectrum, cm-1 :
3004as , 2919s ν(C-H); 1386as δ(C-H); 865 ρ(C-H); 567as ν(C-Sb). Some physical properties and
yield of all the compounds synthesized in this project are summarized in Table 1.

IV. 2. Synthesis of arylcyanoxime ligands (HL)
General Considerations. Arylcyanoximes were synthesized by the Meyer reaction
shown in Figures 11 and 12. The initial compounds for these reactions are commercially
available from Aldrich. These reagents were used by my previous colleagues in the lab for the
synthesis of their compounds, like oximino (2,4-dichlorophenyl) acetonitrile, H(2,4-diCl-PhCO)
and 2-cyano-2-isonitrosothioacetamide, H(TCO).60,82.
In an Erlenmeyer flask, 0.404g (0.0176 mol) of sodium metal was dissolved in 60mL of
propanol under argon flow. This solution was transferred to an Erlenmeyer flask with a solution
of the starting acetonitrile NC-CH 2 -R, compound (2.65 g; 0.0175 mol for monosubstituted,
0.0142 mol for disubstituted) dissolved in 100mL propanol. Cold sulfuric acid was then added
dropwise to a solution 22 g (0.319 mol) of sodium nitrite (NaNO 3 ) dissolved in 50:50 mL of
water and methanol in a round-bottomed flask to create the gaseous methylnitrite, CH 3 -ONO that
bubbled through the Erlenmeyer flask with the initial acetonitrile. Passing gaseous methylnitrite
26

immediately changes color of solution to yellow and after ~15 min the reaction mixture was
purged with N 2 gas and left in the cold (+4 °C) overnight. TLC was ran on the solution against
the initial compounds before the experiment was continued to confirm the formation of the
product. The solvent was removed from the solution using rotary evaporator and the yielding
yellow solid of Na-Ligand was dissolved in about 20 mL of water and acidified with a 1:5
solution of water and sulfuric acid (H 2 SO4 ) until pH ̴ 4. The protonated oxime was then washed
with ether and brine solution to extract the organic (ether) layer with the oxime. The ether layer
was dried and stored in the fridge overnight. Then the ether was removed with Rotovap, and the
white solid cyanoxime was dried in a desiccator over H 2 SO4 .

Figure 11. The general reaction used preparation of monosubstituted arylcyanoximes.
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Synthesis of Oximino (2-chlorophenyl) Acetonitrile, H(2-Cl-PhCO). The initial
compound used was 2-chlorobenzyl cyanide (97%), purchased from Sigma Aldrich, #18,849-2.
Figure 11 illustrates the procedure for the synthesis of the compound. The melting point of the
target compound was 124.43 °C. The yield of the product was 0.944 g (30%), Rf value of 0.29
(EtOAc/hexane = 1:4). The 1 H NMR spectrum in dmso-d 6 , ppm: 14.08 (1H, singlet, oxime
group), 7.65 (1H, doublet), 7.63 (1H, multiplet, Ar H), 7.59 (1H, multiplet, Ar H), 7.50 (1H,
multiplet, Ar H). IR spectrum, cm-1 : 3334 ν(O-H); 3075 ν(C-H); 2236 ν(C≡N); 1670 ν(C=N);
1581 ν(C=C); 965 ν(N-O); 756 δ(C-H); 700 - 500 ν(C-Cl).
Synthesis of Oximino (4-chlorophenyl) Acetonitrile, H(4-Cl-PhCO). The initial
compound used for this synthesis was 4-chlorobenzyl cyanide (97%), purchased from Sigma
Aldrich, #C2, 800-6. The melting point was 95 °C.10 The yield of the product, H(4Cl-PhCO) was
0.692 g (22%), Rf value of 0.32 (EtOAc/hexane = 1:4). The IR spectrum, cm-1 : 3281 ν(O-H);
2972 νs (C-H); 2251 ν(C≡N); 1594 ν(C=N); 1488 ν(C=C); 964 ν(N-O); 826 δ(C-H); 487 ν(C-Cl).
Synthesis of Oximino (2,4-dichlorophenyl) Acetonitrile, H(2,4-diCl-PhCO). The
initial compound used was 2,4-dichlorophenyl acetonitrile81 purchased from Sigma Aldrich, #17846-2, while the reaction is displayed in Figure 12. The melting point was 133.51°C. The yield
of the product was 2.3 g (73%), Rf value of 0.37 (EtOAc/hexane = 1:4). IR spectrum, cm-1 : 3277
ν(O-H); 3155 ν(C-H); 2245 ν(C≡N); 1583, 1474 ν(C=C); 1421 ν(C=N); 1090, 632 ν(C-Cl);
1034, 969 ν(N-O); 818, 755 δ(C-H).
Synthesis of oximino (2,6-dichlorophenyl) acetonitrile, H(2,6-diCl-PhCO). The initial
compound used was 2,6-dichlorophenyl acetonitrile82 purchased from Sigma Aldrich, #12,601-2.
The melting point was 99.61 °C. The yield of the product was 0.283 g (60%), Rf value of 0.32
(EtOAc/hexane = 1:4). The 1 H NMR, ppm: 14.41 (1H, s, oxime group), 7.68 (2H, multiplet),
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7.59 (1H, multiplet).

13 C

NMR, ppm: 135.26 (carbons at 2,6-positions), 133.26 (carbons at 3,5-

positions), 129.07 (carbon at 4-position), 127.27 (carbon at 1-position), 129.64 (oxime carbon),
114.29 (CN-group). IR spectrum, cm-1 : 3420 (O-H); 3171, 3083 (C-H); 2250 (C≡N); 1577,
1559 (C=C); 1431 (C=C) - Ph-group pulsing; 725, 783, 794 (C-H) - 1,2,3-Ph-group pattern;
1411 (C=N); 1047 (N-O); 1126as , 1083s (C-Cl).

Figure 12. Scheme for making disubstituted arylcyanoximes.

For the preparation of trimethylantimony (V) cyanoximates, it was necessary to make either
Ag(I) or Tl(I) cyanoximates. Some ligands with Ag(I) do not form stable complexes –
thioamides and aryl cyanoximes. These complexes were highly light sensitive compared to other
complexes of Ag(I) synthesized in the lab. Therefore, Tl(I) was necessary to be able to form
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stable complexes for the metathesis reaction to proceed. Tl(I) also shares a lot of similarities with
Ag(I), making it a successful replacement for our reactions.

IV. 3. Synthesis of Silver (I) and Thallium (I) Complexes from HL
There were several silver (I) cyanoximates already prepared in our laboratory by previous
colleagues and their synthesis was unnecessary because they were available. The Ag-Ligand
form chosen for the metathesis reactions with SbMe3 Br2 were Ag(MCO), Ag(ECO) and
Ag(ACO). Other cyanoximes, such as thioamides and haloaryl, do not form stable Ag(I)
compounds and for the organoantimony (V) compounds, Tl(I) were necessary. Thioamide based
cyanoximes, H(TCO) and H(TDCO) were also available in the laboratory, but their thallium
cyanoximates Tl(TCO) and Tl(TDCO)) were synthesized by Dr. Gerasimchuk to prevent
graduate students’ exposure to toxic thallium salts.7 The other TlL syntheses with halogenated
cyanoximes were performed by Dr. Gerasimchuk as well.
The reaction is carried out on a hot plate, where a hot solution of thallium carbonate
(Tl2 CO3 ) is made by dissolving it in 13 mL of water. In small portions, the HL is added, and
carbon dioxide is evolved. A yellow solution is formed is filtered while hot in a large-mouthed
test tube already submerged into hot water (about 55 °C) in a large Dewar flask. The thallium
solution is then left to slowly crystallize over several days. One example of the synthesis is
illustrated in Figure 13. Thus, Thallium (I) salts; Tl(2-Cl-PhCO) had a yield of 0.2690 g (36.6%)
based on 0.346 g of H(2-Cl-PhCO). The Tl(4-Cl-PhCO) had a yield of 0.5551 g (64.62%) based
on 0.404 g of H(4-Cl-PhCO). The Tl(2,4-diCl-PhCO) had a yield of 0.8242 g (64.4%) based on
0.658 g of H(2,4-diCl-PhCO). The Tl(2,6-diCl-PhCO) had a yield of 0.2809 g (19.2%) based on
0.7511 g of H(2,6-diCl-PhCO).

30

A

B
Figure 13. General scheme for synthesis of Tl-Ligand salts from H-Ligands for (A) mono- and
(B) disubstituted arylcyanoximes.

IV. 4. Synthesis of Antimony Cyanoximates (SbMe3 L2 ): The Metathesis Reaction
Trimethylantimony (V) cyanoximates were prepared via metathesis reaction shown in
Figure 14. Trimethylantimony (V) dibromide is dissolved in about 5 mL of acetonitrile or
propionitrile with the help of a sonicator. The Tl(L) is then added carefully to the solution under
stirring. There is a color change from yellow to colorless/clear for all cyanoximes except TCO and TDCO -. The reaction is fast and after ̴ 10 mins, the precipitate of AgBr or TlBr was
separated via centrifuge. Complete separation required 3 mins using the Thermo-Scientific
Sorvall Legends Micro 17 at 10,000 rpm (Figure 16). After centrifugation, the liquid, now
containing trimethylantimony (V) cyanoximate was transferred into a small beaker
crystallization80 in a desiccator charged with paraffin. The general pictorial sequence of the
procedure is shown in Figure 15. For metathesis reaction with AgL, this procedure was carried
out under a red-light lamp to prevent the decomposition of the light-sensitive silver salts.60,80
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Figure 14. General scheme for antimony cyanoximate metathesis reaction. L represent the ligands
used in the synthesis.

Figure 15. General sequence of procedures for the metathesis reaction shown in Figure 5.

Synthesis of SbMe3 (2-Cl-PhCO)2 . The 0.08507g (0.2604 mmol) of SbMe3 Br2 and
0.2000g (0.5209 mmol) of Tl(2-Cl-PhCO) was used in the metathesis reaction (Figure 5). The
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yield of the dry product was 0.1100 g (80.3%) based on SbMe3 Br2 . The melting point was
128.78°C. The IR spectrum, cm-1 : 3067, 3029, 2921 ν(C-H); 2219 ν(C≡N); 1590 ν(C=N); 1518,
1479 ν(C=C); 1470, 755 δ(C-H); 974 ν(N-O); 651 ν(C-Cl); 586 ν(C-Sb)as .
Synthesis of SbMe3 (4-Cl-PhCO)2. The 0.1700 g (0.5204 mmol) of SbMe3 Br2 and
0.4000g (1.042 mmol) of Tl(4-Cl-PhCO) was used in the metathesis reaction (Figure 14). The
yield of the dry product was 0.1211g (44.2%) based on SbMe3 Br2 . The melting point was
162.27°C. The IR spectrum, cm-1 : 3072, 2966, 2932 ν(C-H); 2220 ν(C≡N); 1594 ν(C=N); 1489
ν(C=C); 1489, 1397, 821 δ(C-H); 972 ν(N-O); 710 ν(C-Cl); 544 ν(C-Sb)as .
Synthesis of SbMe3 (2,4-diCl-PhCO)2 . The 0.1570 g (04806 mmol) of SbMe3 Br2 and
0.4000 g (0.9560 mmol) of Tl(2,4-diCl-PhCO) was used in the metathesis reaction (Figure 14).
The yield of the dry product was 0.2130 g (74.0%) based on SbMe3 Br2 . The melting point was
129.18°C. The IR spectrum, cm-1 : 3087 ν(C-H); 2219 ν(C≡N); 1585 ν(C=N); 1498 ν(C=C);
1379, 851 δ(C-H); 979 ν(N-O); 821 ν(C-Cl); 570 ν(C-Sb)as .
Synthesis of SbMe3 (2,6-diCl-PhCO)2 . The 0.07807 g (0.2390 mmol) of SbMe3 Br2 and
0.2000 g (0.4870 mmol) of Tl(2,6-diCl-PhCO) was used in the metathesis reaction (Figure 14).
The yield of the dry product was 0.1010 g (71.0%) based on SbMe3 Br2 . The melting point was
184.35 °C. The IR spectrum, cm-1 : 3089, 3077, 2933 ν(C-H); 2217 ν(C≡N); 1583 ν(C=N); 1561,
1526 ν(C=C); 1430, 777, 725 δ(C-H); 972 ν(N-O); 632 ν(C-Cl); 561 ν(C-Sb)as .
Synthesis of SbMe3 (TCO)2 . The 0.1956 g (0.5988 mmol) of SbMe3 Br2 and 0.4000 g
(1.203 mmol) of Tl(TCO) was used in the metathesis reaction (Figure 14). The yield of the dry
product was 0.03100 g (12.2%) based on SbMe3 Br2 . The melting point was from 186.9 - 189.6
°C. The 1 H NMR spectrum in DMSO-d 6 , ppm: 14.34, 10.5 (NH 2 group in syn-); 9.98, 9.53 (NH 2
group in anti-). 13 C{1 H} NMR spectrum in dmso-d 6 , ppm: 186.51 (thioamide, anti-), 185.91
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(thioamide, syn-), 133.36 (oxime group, syn-), 131.79 (oxime group, anti-), 109.47 (CN group,
syn-), 108.83 (CN group, anti-). The IR spectrum, cm-1 : 3440, 3389 ρ(NH 2 ); 2922 ν(C-H); 2236
ν(C≡N); 1693 ν(C=N); 1472, 1331 δ(C-H); 1180, 1068 ν(C=S)a 981 ν(N-O); 591 ν(C-Sb)as .
Synthesis of SbMe3 (TDCO)2 . The 0.1168 g (0.3575 mmol) of SbMe3 Br2 and 0.2579g
(0.7153 mmol) of Tl(TDCO) was used in the metathesis reaction (Figure 14). The yield of the
dry product was 0.1023 g (41.5%) based on SbMe3 Br2 . The melting point was 175.27 °C. 1 H
NMR spectrum in DMSO-d 6 , ppm: 3.45, 3.40 (6H, singlet, CH 3 - groups tertiary amineaccidental overlap), 3.35, 3.17 (3H singlet, CH 3 - groups tertiary amine), 1.79, 1.77, 1.75 (3H,
singlet, CH 3 - group Sb). 13 C{1 H} NMR spectrum in dmso-d 6 , ppm: 183.72 (thioamide, anti-),
182.67 (thioamide, syn-), 133.96 (oxime group, syn-), 132.15 (oxime group, anti-), 114.55 (CN
group, syn-), 110.09 (CN group, anti-). The IR spectrum, cm-1 : 2932 ν(C-H); 2225 ν(C≡N); 1531
ν(C=N); 1449, 1394 δ(C-H); 1141, 1078, 1050 ν(C=S)a, 969 ν(N-O); 568 ν(C-Sb)as .
Synthesis of SbMe3 (ACO)2 . The 0.2000 g (0.6122 mmol) of SbMe3 Br2 and 0.2693 g
(1.224 mmol) of Ag(ECO)was used in the metathesis reaction (Figure 14). The yield of the dry
product was 0.0250 g (10.4%) based on SbMe3 Br2 . The IR spectrum, cm-1 : 3406 ρ(NH 2 ); 2935
ν(C-H); 2228 ν(C≡N); 1684 ν(C=O)a, 1600 ν(C=N); 1423, 1312 δ(C-H); 981 ν(N-O); 587 ν(CSb)as .
Synthesis of SbMe3 (ECO)2 . The 0.2000 g (0.6122 mmol) of SbMe3 Br2 and 0.3049 g
(1.225 mmol) of Ag(ECO)was used in the metathesis reaction (Figure 14). The yield of the dry
product was 0.2220 g (80.8%) based on SbMe3 Br2 . The melting point was 140.52 °C. 1 H NMR
spectrum in DMSO-d 6 , ppm: 4.31 (2H, multiplet, CH 2 -group ECO -), 1.89, 1.71 and 1.67 (3H,
singlet, CH 3 -group Sb), 1.28 ( 3H, multiplet, CH 3 -group ECO -). 13 C{1 H} NMR spectrum in
dmso-d 6 , ppm: 159, 127 ( oxime carbons), 109.59 (CN-group), 62.08 (CH 2 - group ECO -), 14.47
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(CH 3 - group ECO -), 8.33, 7.10, 6.63 (CH 3 - group Sb). The IR spectrum, cm-1 : 2996, 2967, 2940
ν(C-H); 2230 ν(C≡N); 1716 ν(C=O)a; 1465, 1372 δ(C-H); 1060 ν(N-O); 583 ν(C-Sb)as .
Synthesis of SbMe3 (MCO)2 . The 0.1636 g (0.5008 mmol) of SbMe3 Br2 and 0.2922 g
(1.008 mmol) of Ag(MCO)was used in the metathesis reaction (Figure 14). The yield of the dry
product was 0.1023 g (77.3%) based on SbMe3 Br2 . The melting point range was from 118.5 120.9 °C. The IR spectrum, cm-1 : 2965, 2935 ν(C-H); 2224 ν(C≡N); 1634 ν(C=O)a; 1460, 1390
δ(C-H); 930 ν(N-O); 589 ν(C-Sb)as .

A

B

Figure 16. Instrumentation used in synthesis. A) Thermo Scientific Sorvall Legends Micro 17 and
B) Fisher Scientific Vortex.
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Table 1. Elemental analysis, yield and color of initial compounds, ligands, and antimony cyanoximates
Elemental Analysis, Element %
Compound

Melting point (°C)

Yield (%)

C, % Calc. (Found) H, % Calc. (Found) N, % Calc. (Found)

SbMe3 Br2

183.2 - 183.5

23-25

N/A

N/A

N/A

H(2-Cl-PhCO)

124.43

30

N/A

N/A

N/A

H(4-Cl-PhCO)

9583

22

N/A

N/A

N/A

H(2,4-diCl-PhCO)

133.51

73

N/A

N/A

N/A

H(2,6-diCl-PhCO)

99.61

60

44.68 (44.75)

1.87 (1.94)

13.03 (13.12)

Tl(2-Cl-PhCO)

N/A

36.6

25.02 (25.30)

1.05 (0.88)

7.30 (7.18)

Tl(4-Cl-PhCO)

N/A

64.6

25.02 (25.91)

1.05 (0.92)

7.30 (7.26)

Tl(2,4-diCl-PhCO)

N/A

64.4

22.96 (24.66)

0.72 (0.67)

6.70 (6.86)

Tl(2,6-diCl-PhCO)

N/A

19.2

22.96 (22.19)

0.72 (0.64)

6.70 (6.36)

SbMe3 (2-Cl-PhCO)2

128.78

80.3

N/A

N/A

N/A

SbMe3 (4-Cl-PhCO)2

162.27

44.2

43.38 (43.33)

3.26 (3.35)

10.65 (10.39)

SbMe3 (2,4-diCl-PhCO)2

129.18

74.0

38.36 (38.07)

2.54 (2.43)

9.42 (9.35)

SbMe3 (2,6-diCl-PhCO)2

184.35

71.0

N/A

N/A

N/A

SbMe3 (TCO)2

186.9 - 189.6

10.4

N/A

N/A

N/A

SbMe3 (TDCO)2

175.27

41.5

32.58 (32.77)

4.42 (4.36)

17.54 (17.47)

SbMe3 (ACO)2

N/A

8.0

N/A

N/A

N/A

SbMe3 (ECO)2

140.52

80.8

N/A

N/A

N/A

SbMe3 (MCO)2

118.5 - 120.9

77.3

N/A

N/A

N/A

* N/A = sample data was not recorded.
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V. RESULTS & DISCUSSIONS
X-ray Single Crystal Analysis
Block-type single crystals, suitable for the X-ray analysis, were obtained in two ways: 1)
during an overlay of pentane over ether solution of the cyanoxime within ~2 weeks at +4 o C in
the thin tube in the refrigerator; 2) using vapor diffusion (ether) method into acetonitrile solution
of the compound. All synthesized compounds in this work were characterized via X-ray
diffraction by Dr. Nikolay Gerasimchuk. That is: a) initial cyanoximes, b) their Tl-derivatives, c)
trimethylantimony(V) dibromide and d) cyanoximates of the latter Sb-source. Total number of
determined crystal structures in this project is 17. Crystallographic output was in a form of the
RES and CIF files that were later used by me for plotting the most representative pictures. Also,
some of the datasets were reprocessed by me (meaning step-by-step structure solution and
refinement) for gaining proficiency in the method and educational purposes. All structures were
solved using direct methods incorporated into the SHELXS - 2013 and refined using the Bruker
SHELXTL Software Packages. 60,84,85 In the case of crystal twins, application of the detwinning
procedure with the help of CELL_NOW followed by absorption correction was accomplished
with the help of TWINABS.84-86 Some of the drawings of molecular structures were done with
ORTEP 3v2, 84, 87 while the other molecular structures and packing diagrams for structures were
performed using the Mercury Program. 57,84,88 The ORTEP drawings (abbreviated from: OakRidge Thermal Ellipsoids Plots) is done at 50% probability.
In this thesis we follow typical way of presentation of crystal structures of chemical
compounds showing I) the ASU first, which is the asymmetric unit; II) GROW mode, which is
actual molecular structure; III) table of the crystal and refinement data; IV) details of the
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structure with emphasis on H-bonding (if present), geometrical features such as stereochemistry;
V) crystal packing diagrams if necessary for comprehension and discussion.

V. 1. Structure and Properties of The Initial Sb-Source Compound
The Crystal Structure of SbMe3 Br2 . All the antimony cyanoximates were made from
SbMe3 Br2 which has pentacoordinated pnictogen atom in formal oxidation state +5. This
compound was prepared using methods previously described 78 without modification. Compound
represents white crystalline substance soluble in common organic solvents and hydrolyzes in
water to a mixture of hydrated products including polynuclear species. Covalently attached
bromine atoms are prone to replacement by better nucleophiles and that makes SbMe3 Br2
excellent starting compound for making new trimethyl-antimony(V) organometallic compounds.
Despite the fact of earlier determination of the crystal structure in the ’70s, we performed redetermination of its structure using modern hardware and processing software. Obtained data are
much better than previously reported. Crystallographic community encourages chemists to
improve quality of old deposited into Cambridge Crystal Structures Datacenter by deposition
better structures into the database.
The crystallographic data for SbMe3 Br2 is shown in Table 2. In solid state this compound
adopts the trigonal bipyramid geometry with equal bond lengths from the metal Sb core to both
bromine atoms (Sb1–Br1) and the three carbon atoms (Sb1–C1) bonded to it. This can be seen
on the ASU unit in Figure 17A. The distances are 2.653 Å and 2.103 Å, respectively. The
measured valence angles are as follows: Br1-Sb1-Br1 = 180 °, Br1-Sb1-C1 = 90 °, and C1-Sb1C1 = 120 ° (Figure 18). The SbMe3 Br2 represents a compound with D3h point group symmetry
of non-H atoms with a 3-fold principal axis, 2-fold axes and a set of mirror planes. Figure 17B
shows multiple positions for H-atoms originated from their Site Occupancy Factor (SOF) for
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each H-atom is 0.25 because of their hosting C-atom occupying the mirror plane. For each
hydrogen to have SOF = 1, there must be 4 H-atoms with SOF 0.25. Thus, there are 3 hydrogen
atoms distributed between four positions totaling in occupancy to 1 and attached to the hosting
single carbon atom generating 12 H-atoms in total on the methyl carbon. Figure 18 shows bond
lengths and valence angles in the structure of this important precursor for the rest of reported
here trimethylantimony(V) cyanoximates.

Figure 17. The molecular structure and numbering scheme for SbMe 3 Br2 . The ASU in the
structure (A), and the GROW fragment (B). Symmetry operations for positions : _2: -y, x-y, z; _5:
y, -x-y, z+1/2; and _8: x-y, -y, -z.
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Table 2. Crystal and refinement data for SbMe3 Br2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

SbMe3 Br2
C2 H6 Br1.33 Sb
258.36
120(2)
0.71073
0.142×0.09×0.08
colorless needle
hexagonal
P 63 /mmc
a = 7.298(2)
α = 90
b = 7.298(2)
β = 90
c = 8.842(3)
γ = 120
407.8(3)
3
3.156
14.700
347
3.22 to 27.00
-9 ≤ h ≤ 9
-9 ≤ k ≤ 9
-11 ≤ l ≤ 11
4422
200 [Rint = 0.0250]
0.7465 and 0.4474
200 / 0 / 11
1.091
162 data;
R1 = 0.0141
wR2 = 0.0362
R1 = 0.0186
wR2 = 0.0381
0.795 and -0.294

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3
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Figure 18. Trigonal bipyramid geometry of SbMe3 Br2 showing valence angles (A) and bond
lengths (B) in the molecule.

V. 2. Crystal Structures of Organic Ligands Used for The Preparation of Sb(V)
Compounds
Previously we observed formation of mixtures of two diastereomers of cyanoximes – syn
and anti – as the result of the nitrosation reaction, 89 and both are kinetic products since overall
reaction is thermodynamically facile and typically affords desired compound in high yield.67,90
Rotation of the NO-group around N-C bond during the nitrosation reaction leads to the formation
of the syn-diastereomer. Most of the time we observed crystallization of just one, more favorable
anti-diastereomer. However, isolation of pure individual syn-diastereomers was accomplished
prior to this work in only two cases in work by the former student Leon Goeden. 82 Thus, a series
of halogenated both monosubstituted 83 and disubstituted-arylcyanoximes83,91 have been
synthesized and initially characterized in Dr. Gerasimchuk’s laboratory some time ago. Crystal
structures of some of them have been reported earlier57,91 including the anti-isomer of the H(2,6-
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diCl-PhCO).67 This diastereomer crystallizes in rare tetragonal non-centrosymmetric space group
P43 21 2 with unit cell parameters a = b = 7.804 Å, c = 31.713 Å; V = 1931.8 Å 3 .
In general, being weak organic acids families of both groups of both monosubstituted and
disubstituted-arylcyanoximes undergo deprotonation in aqueous and non-aqueous solutions with
the formation of yellow-colored anions due to n→* transition in the >C-N-O fragment. Their
electronic structure can be described as an average between several resonance forms with charge
delocalization among functional groups.93 There is a significant contribution of the nitroso- form
of the anion. Ionic cyanoximates in their alkali metal salts67,89 adopt planar structures in which
bond lengths indicate conjugation between functional groups in the molecule. This conjugation,
for instance, can be seen from the shift to low wavenumbers and significant intensity increase for
the (C≡N) vibration in the IR-spectra of Cat +L-- as compared to HL (Cat + = Na, K, Cs; L- =
cyanoxime anion). It should be noted in context of this study that both mono- and di-halogenated
arylcyanoximes form Werner-type complexes with metal ions such as Pd, Pt,67 and especially
Tl.57.67,83
The Crystal Structure of syn-H(2,6-diCl-PhCO). This compound was found to be able
to crystallize as separate diastereomers: anti- and syn-, depending on the solvent and
crystallization conditions. A rare case of pure syn- diastereomer is described here. Thus, looking
back at previous studies the anti-isomer was obtained upon slow crystallization of the
ether/acetone solution, while syn-isomer crystallized from a long tube containing overlaid with
hexane ether/acetonitrile solution. Grown in the latter case, large crystals on the tube wall were
harvested and used for structure determination. Molecular structure of this diastereomer is
displayed in Figure 19. Crystal and refinement data are presented in Table 3, while the most
important bonds and valence angles are summarized in Table 4. Similarly, to its anti-isomer this
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compound has highly non-planar structure with a large dihedral angle =74.29 o between two
planar fragments: chloro-aryl and cyanoxime (Figure 19). In the crystal structure of anti-H(2,6diCl-PhCO) this angle has surprisingly (and counterintuitively) slightly larger value of: =77.1
o .59,67

Figure 19. Molecular structure and numbering scheme for syn-H(2,6-diCl-PhCO) (in ORTEP
representation drawn at 50% thermal ellipsoids probability level) showing two orthogonal views
and a large dihedral angle between two planar fragments.

Molecules in the structure of the syn-H(2,6-diCl-PhCO) diastereomer in the crystal form
rarely observed H-bonding via OH-group and N-atom of the nitrile group forming zigzag chain
running along c-direction (Figure 20). Overall structure is columnar with − stacking
interactions between neighboring di-chloroaryl fragments where inside the column there are
alternating coplanar and angled at ~18.6 o arrangements (Figure 21A). Aside of H-bonding there
are other short intermolecular van-der-Waals and electrostatic contacts ranging from 3.27 to 3.44
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Å highlighted in Figure 21B. Those include phenyl-group centroid to Cl atom and C-H---C-H
interactions between slipped parallel -systems.

Table 3. Crystal and refinement data for syn-H(2,6-diCl-PhCO).
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

syn-H(2,6-diCl-PhCO)
C8 H4 Cl2 N2O
215.03
100.6(7)
1.54184
0.24×0.15×0.12
colorless
Monoclinic
P2/c (#13)
a = 8.1720(2)
α = 90
b = 8.8013(3)
β = 102.546(3)
c = 13.0146(4)
γ = 90
913.71(5)
3
1.563
6.064
347
5.025 to 76.592
-9 ≤ h ≤ 9
-9 ≤ k ≤ 9
-11 ≤ l ≤ 11
8213
1877 [Rint = 0.0348]
N/A
1877 / 0 / 122
1.107
162 data;
R1 = 0.0459
wR2 = 0.1268
R1 = 0.0471
wR2 = 0.1280
0.795 and -0.294

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

44

A

B

Figure 20. Geometry of H-bonding in the structure of syn-H(2,6-diCl-PhCO) showing bond and
angle in C≡N---H-O fragment: A – pruned view of the chain along a-direction; B – along bdirection.

Comparison of crystal structures of two diastereomers intuitively suggests that the synisomer is more compact due to an inward orientation of the oxime fragment. Indeed this is the
case: density of the syn-isomer is greater (d=1.5631 g/cm3 ) as for the anti-isomer (d=1.479
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g/cm3 ), and the structure of discussed in this work syn-diastereomer occupies 62.5% of the unit
cell volume (Table 3) as compared for the 58.1% value in the anti-diastereomer.67

A

B

Figure 21. Organization of crystal packing in the columnar structure of syn-H(2,6-diCl-PhCO):
A – formation of zigzag column running along c-direction showing parallel c-direction; B – all
short intermolecular contacts in the structure.
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Table 4. Selected* bond lengths and valence angles (degrees) for the cyanoxime fragment in two
structurally characterized anti- and syn-(bis-chlorinated) arylcyanoximes.
anti- & syn-H(2,6-diCl-PhCO)
anti-H(2,6-diCl-PhCO) [data from ref. 67]
syn-H(2,6-diCl-PhCO)
Bond length, Å
O(1)-N(1)
1.352
O(1)-N(1)
1.368(3)
N(1)-C(7)
1.323
N(1)-C(1)
1.292(3)
N(2)-C(8)
1.134
N(2)-C(2)
1.145(3)
C(1)-C(7)
1.474
C(1)-C(2)
1.442(3)
C(7)-C(8)
1.439
C(1)-C(3)
1.485(3)
o
Valence angle,
C(7)-N(1)-O(1)
108.1
C(7)-N(1)-O(1)
111.3(2)
N(1)-C(7)-C(8)

124.0

N(1)-C(7)-C(8)

127.3(2)

N(1)-C(7)-C(1)

116.2

N(1)-C(7)-C(1)

114.4(2)

C(8)-C(7)-C(1)

119.8

C(8)-C(7)-C(1)

118.2(2)

N(2)-C(8)-C(7)

177.2

N(2)-C(8)-C(7)

176.4(3)

* - geometry of the phenyl group with attached halogen atoms is normal and not shown.

The Crystal Structure of H(TDCO). This compound was obtained first time in 1992 by
Konstantin Domasevitch,93 who was working in Prof. Gerasimchuk research group, but was
never crystallographically characterized. The only available structure for this thioamidecyanoxime is in its Tl-complex: Tl(TDCO).94 The crystal and refinement data are shown in Table
5. The asymmetric unit (ASU) in the structure of this thioamid e-cyanoxime H(TDCO) is
presented in Figure 22. Important bonds/angles are shown in Figure 23. In this structure the
cyanoxime adopts trans-anti geometry. The molecule is highly non-planar with dihedral angle
between the cyanoxime and the thioamide groups being 60.80° as shown in Figure 24. Hydrogen
bonding leads to the formation of chains within the crystal structure of H(TDCO). This can be
seen in Figure 25 along this the hydrogen bond lengths. The parameters for this rare hydrogen
bond between sulfur and the oxime hydrogen are O1-H1O1---S1 = 2.24(4) Å, H1O1---S1 =
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3.154(2) Å with <DHA = 152(3). This is very rare case of the S---H-O- hydrogen bonding. Other
intermolecular forces such as electrostatic and van-der-Waal further stabilize the crystal
structure. This thioamide-cyanoxime H(TDCO) is the only precursor for synthesis of complexes
based on this ligand. Using protonated cyanoxime it was possible to prepare its Cs + and then Tl+
salts with the latter being the most important starting compound for preparation of trimethylantimony(V) cyanoximates.

Figure 22. The ASU in the structure of one of the initial compounds H(TDCO) showing atomic
numbering scheme.
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B

A

Figure 23. Some geometrical details in the structure of H(TDCO): A – valence angles; B –
selected bond lengths. H-atoms are omitted for clarity.

Figure 24. Dihedral angle between mean planes for the thioamide and the cyanoxime groups.
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Table 5. Crystal and refinement data for H(TDCO).
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

H(TDCO)
C5 H7 N3 OS
157.20
100(2)
0.71073
0.217×0.183×0.165
yellow
monoclinic
P21 /c
a = 9.9455(11)
α = 90
b = 6.5012(8)
β = 106.840(2)
c = 12.0927(14)
γ = 90
748.36(15)
4
1.395
0.366
328
2.14 to 26.00
-12 ≤ h ≤ 12
-8 ≤ k ≤ 8

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

-14 ≤ l ≤ 14
7407
1461 [R(int) = 0.0617]
0.745 and 0.615
1461 / 0 / 119
1.076
1215 data;
R1 = 0.0469
wR2 = 0.1233
R1 = 0.0562
wR2 = 0.1289
0.682 and -0.230
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Figure 25. H-bonding distances viewed along b - axis.

The Crystal Structure of “Cs(TDCO)”. The Cs-salt was obtained using Cs2 CO 3 and
H(TDCO) at room temperature. Block-type crystals grew from aqueous solution in plastic vial
dark within ~2 months under inert conditions (Ar). It turned out that after structure solution, the
compound had formula Cs(TDCO)×H(TDCO) representing an acid salt of monoxime.95 There
are two types of those salts: one with equidistant position of the bridging H-atom between two
identical anions (somewhat like HF2 - anions), and the second one with practically co-crystallized
in one lattice protonated oxime HL and its CatL salt (Cat = NH 4 +, Na+, K+). Cases of formation
of this type of compounds are known, but very rare.
Crystal and refinement data for this salt are shown in Table 6. The asymmetric unit
(ASU) in the structure of Cs(TDCO)×H(TDCO) is shown in Figure 26. Selected bond lengths
and valence angles are presented in Table 7. The structure is rare case of an acid salt 89 , but not of
Cat{HL2 } type previously observed for Na+ and K + salts.82,96 In this case, however, this acid salt
has a distinctive anion and a distinctive protonated ligand contrary to many of those with
equidistant position of the hydrogen atom between the cyanoximes. 89 The cesium atom is not
bound to any specific atom of the cyanoximes moieties as depicted in Figure 26. It rather has a
highly distorted environment with multiple atoms surrounding it with multiple angles as for the
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typical ionic compound. This compound is heavily non-planar due to the bulkiness of the
dimethylamine N(Me)2 fragment in the ligand. The dihedral angle between the cyanoxime group
and the thioamide fragment is 61.61 ° for the anion and 69.21 ° for the protonated oxime. Both
values are much larger than the other complexes of TDCO anion due to the presence of Cs+ ion.
The cyanoxime in both moieties adopt exceedingly rare pure trans-anti- geometry. Their bond
lengths for the cyanoxime group are all acceptable and within the expected range. Hydrogen
bonding helps secure the lattice structure as well as electrostatic and van-der-Waal forces.89
Hydrogen bonding is made possible by the protonated ligand within the structure (Figure 26).

Figure 26. The ASU in the structure of Cs(TDCO)×H(TDCO) depicting the numbering scheme.
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Table 6. Crystal and refinement data for the acid salt of Cs(TDCO)×H(TDCO).
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

Cs(TDCO) ×H(TDCO).
C5 H6 CsN 3 OS
223.15
100.15
0.71073
0.117×0.105×0.091
orange
triclinic
P- 1
a = 6.4244(6)
α = 105.1810(10)
b = 10.2553(10)
β = 101.3430(10)
c = 13.3679(13)
γ = 96.8400(10)
819.74(14)
4
1.8080
2.525
436.1
4.18 to 56
9≤h≤9
-15 ≤ k ≤ 15
-19 ≤ l ≤ 19
13640
3932 [Rint = 0.0774, Rsigma = 0.1059]
0.7645 and 0.6950
3932/2/193
0.937
R1 = 0.0411
wR2 = 0.0948
R1 = 0.0485
wR2 = 0.0988
1.00 and -1.05
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Table 7. Selected bond lengths and valence angles of the ligand Cs(TDCO)xH(TDCO).
Cs(TDCO)xH(TDCO).
Valence angle,o
C1 - N1 - O1
114.3(3)
C2 - C1 - N1
114.0(4)
N1 - C1 - C3
128.0(4)
C3 - C1 - C2
117.3(4)
N2 - C2 - C1
179.1(4)
N3 - C3 - S1
125.0(3)
N3 - C3 - C1
118.6(4)
C1 - C3 - S1
116.3(3)

Bond length, Å
O1 - N1
1.345(4)
N1 - C1
1.297(5)
C1 - C2
1.448(6)
C1 - C3
1.491(5)
C2 - N2
1.149(5)
C3 - N3
1.324(5)
C3 - S1
1.674(4)

V. 3. Tl- Cyanoximates.
All the Tl(I)-cyanoximates were prepared by Dr. Gerasimchuk to avoid graduate
students’ exposure to stench or toxic chemical compounds. These were all precursors for the
antimony cyanoximates synthesized.
Crystal structure of Tl(4-Cl-PhCO). Selected bond lengths and valence angles within
the molecule are presented in Table 8. The crystal and refinement data are shown in the Table 9.
The asymmetric unit (ASU) structure of Tl(4-Cl-PhCO) is shown in Figure 27. All the hydrogens
within the complex were identified on the electron difference map and refined to create this ASU
structure. The cyanoxime anion adopts an anti-geometry with no trans or cis assignment of
geometry since the chlorine atom is in the para position to the cyanoxime fragment. The two
fragments present within the molecule are the chloro-aryl group and the cyanoxime group. Both
fragments are planar, but the molecule is non-planar. This is due to the dihedral angle between
the chloro-aryl group and the cyanoxime group which is 9.47 °. This angle was calculated using
mean planes Cl1-C6-C7-C8-C3-C4-C5 and N2-C3-C1-N1-O1, respectively. This is very similar
to the structure of ligand H(4-Cl-PhCO) and metal complex Tl(4-Br-PhCO).57 The bond lengths
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for N1-C1 = 1.308(7) Å and N1-O1 = 1.340(6) Å are within range of bond lengths observed for
the cyanoxime group in similar classes of compounds. When compared to the ligand H(4-ClPhCO),57 the bond lengths are 1.289 Å and 1.378 Å respectively, with differences between bond
lengths for the ligand and the metal complex attributed to the redistribution of the electron
density in the C-N-O fragment during the complexation to the metal Tl center. 57,67 Interestingly,
the sum of these bond lengths in both the ligand and the metal complex are almost identical with
2.667 Å for H(4-Cl-PhCO) and 2.648 Å for Tl(4-Cl-PhCO). The π-π stacking interactions
between 4-chlorophenyl rings of neighboring molecules holds the structure together in packing
with the distance between the 2 closest centroids of the 4-chlorophenyl rings being 4.085 Å.
Intra- and inter molecular forces, along with van-der-Waal forces are also present to stabilize the
crystal structure.

Figure 27. The ASU in the structure of one of the initial compounds Tl(4-Cl-PhCO) drawn in
ORTEP representation at 50% ellipsoid probability level showing atomic numbering.

55

Table 8. Crystal and refinement data for Tl (4-Cl-PhCO).
Parameter
Empirical formula
Formula weight, g/mol

Tl (4-Cl-PhCO)
C8 H4 ClN 2 OTl
383.95
296(2)
0.71073
0.193×0.051×0.041

Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group

lemon - yellow
monoclinic
P 1 21/n 1

Unit cell dimensions, Å, °

a = 10.951(4)
α = 90
b = 4.0853(15)
β = 99.041(4)
c = 20.616(7)
γ = 90
910.9(6)
4
2.800
17.980
688

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °

2.00 to 28.90

Index ranges

-14 ≤ h ≤ 14
-5 ≤ k ≤ 5
-27 ≤ l ≤ 28

Reflections collected
Independent reflections

10544
2391 [Rint = 0.0544]

Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]

0.641 and 0.327
2391 / 0 / 130
1.025
1893 data; R1 = 0.0362
Wr2 = 0.0829

R indices [all data]

R1 = 0.0490
Wr2 = 0.0892
1.857 and -2.041

Largest diff. peak and hole, e Å -3
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Table 9. Selected bond lengths and valence angles of the ligand Tl(4-Cl-PhCO).
Tl(4-Cl-PhCO)
Bond length, Å

Valence angle, °

O1 - N1

1.340(6)

C1 - N1 - O1

115.9(4)

N1 - C1

1.308(7)

C2 - C1 - N1

119.4(5)

C1 - C2

1.440(8)

N1 - C1 - C3

120.1(5)

C1 - C3

1.474(8)

C3 - C1 - C2

120.5(5)

C2 - N2

1.133(8)

N2 - C2 - C1

177.6(7)

Cl1 - C6

1.734(6)

N1 – O1 - TlO1

90.3(3)

Crystal structure of Tl(2,4-diCl-PhCO). Selected bond lengths and valence angles can
be seen in Table 10. The crystal and refinement data for Tl(2,4-diCl-PhCO) is presented in Table
11. The ASU is shown in Figure 28. All 3 hydrogens on the phenyl ring were attached and
refined isotropically. The crystal specimen was an inversion twin and forms an elegant dimer
(Figure 29A) when viewed with Hg with both cyanoximes on each side adopting a trans-anti
geometry. This compound was highly non-planar with planar fragments. The dihedral angle, α,
formed between mean planes of the cyanoxime group and the chloro-aryl group was 51.49 °
(Figure 29B). In comparison to the ligand H(2,4-diCl-PhCO), the dihedral angle is almost similar
with 50.61 °.81 The bonds in the cyanoxime group were N1-O1 = 1.294(12) Å and N1-C1 =
1.314(13) Å. These were within the normal ranges for cyanoxime group in similar compounds.
There is no hydrogen bonding present but π-π stacking interactions between the 2,4-chlorophenyl
groups at 3.869 Å contribute to the lattice formation and the overall architecture of the structure.
Compared to the ligand H(2,4-diCl-PhCO) which has π-π stacking interactions at 3.695 Å,81 the
difference can be the presence of H bonding holding parallel sheets of molecules together.

57

Columns within the crystal structure are also held together by van-der-Waal forces between the
4-chloophenyl groups.

Figure 28. The ASU in the structure of one of the initial compounds Tl(2,4-diCl-PhCO) drawn in
ORTEP representation and showing atomic numbering.

Table 10. Selected bond lengths and valence angles of the ligand Tl(2,4-diCl-PhCO).
Tl(2,4-diCl-PhCO)
Valence angle,o

Bond length, Å
O1 - N1

1.294(12)

C1 - N1 - O1

115.8(10)

N1 - C1

1.314(13)

C2 - C1 - N1

121.3(9)

C1 - C2

1.402(13)

N1 - C1 - C3

117.5(9)

C1 - C3

1.466(13)

C3 - C1 - C2

120.4(9)

C2 - N2

1.151(13)

N2 - C2 - C1

177(1)

Cl1 – C8

1.734(9)

Cl2 - C6

1.756(9)
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Figure 29. Molecular structure of Tl(2,4-diCl-PhCO) presented using mercury software package.
(A) Dimeric structure of Tl(2,4-diCl-PhCO). (B) Dihedral angle, α, between the cyanoxime and
the chloro-aryl group.
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Table 11. Crystal and refinement data for Tl(2,4-diCl-PhCO).
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Tl(2,4-diCl-PhCO)
C8 H3 Cl2 N2OTl
418.41
296.15
1.54184
0.186×0.109×0.095
Light-yellow
Monoclinic
C 1 2/c 1
a = 37.013(9)
α = 90
b = 3.8692(10)
β = 107.072(3)
c = 14.624(4)
γ = 90
2002.0(9)
8
2.7761
16.638
1487.0
4.6 to 66.02
-54 ≤ h ≤ 50,
-5 ≤ k ≤ 5,
-21 ≤ l ≤ 21
10667
3433 [Rint = 0.0437]
0.811 and 0.418
3433 / 0 / 122
1.037
R1 = 0.0564
wR2 = 0.1164
R1 = 0.0822
wR2 = 0.1282
2.81 and -3.29

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

Crystal structure of Tl(2,6-diCl-PhCO). Important bond lengths and valence angles are
shown in Table 12. The crystal data for Tl(2,6-diCl-PhCO) is shown in Table 13. The
asymmetric unit for Tl(2,6-diCl-PhCO) is shown in Figure 30. Its crystalline specimen proved
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difficult to work with because it was multidomain, but only main domain reflections were being
used to analyze the crystalline structure. It was found to just be an overlaying of several crystals.
Tl(2,6-diCl-PhCO) forms a dimer (Figure 31), and the cyanoxime adopts an anti-geometry, with
all the H-atoms attached manually to their hosting C-atoms in APEX. The dihedral angle
between the chloro-aryl group and the cyanoxime (Figure 31) was 57.62 ° attesting to the nonplanarity of the compound. The ligand H(2,6-diCl-PhCO)59,67 on the other hand has a dihedral
angle of 77.1 °. The bond lengths for N1-C1 = 1.30(3) Å and N1-O1 = 1.35(2) Å are within the
normal ranges for the cyanoxime bond lengths in similar class of compounds. These are identical
to that of the bond lengths in the ligand H(2,6-diCl-PhCO) with 1.323 Å and 1.352 Å
respectively. Electrostatic attractions are present to stabilize the structure. Furthermore, the
presence of − stacking interactions between neighboring di-chloroaryl fragments and van-derWaal forces help stabilize the crystal structure.

Figure 30. The ASU in the structure of one of the initial compounds Tl(2,6-diCl-PhCO) drawn in
ORTEP representation showing atomic numbering.
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Table 12. Selected bond lengths and valence angles of the ligand Tl(2,6-diCl-PhCO).
Tl(2,6-diCl-PhCO)
Valence angle,o

Bond length, Å
O1 - N1

1.35(2)

C1 - N1 - O1

111.2(18)

N1 - C1

1.30(3)

C2 - C1 - N1

125.0(2)

C1 - C2

1.39(3)

N1 - C1 - C3

115.6(19)

C1 - C3

1.54(3)

C3 - C1 - C2

119.0(2)

C2 - N2

1.13(3)

N2 - C2 - C1

173.0(3)

Cl1 – C4

1.77(2)

Cl2 – C8

1.77(2)
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Table 13. Crystal and refinement data for Tl (2, 6-diCl-PhCO).
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

Tl (2, 6-diCl-PhCO)
C8 H4 Cl2 N2OTl
419.40
150(2)
0.71073
0.143×0.056×0.051
lemon - yellow
monoclinic
P 1 21/n 1
a = 4.070(12)
α = 90
b = 7.73(2)
β = 91.01(5)
c = 31.04(9)
γ = 90
976.(5)
4
2.852
17.047
756
2.63 to 30.52
-1 ≤ h ≤ 5
-10 ≤ k ≤ 10
-31 ≤ l ≤ 33
3816
2440 [Rint = 0.0966]
2440 / 110 / 122
0.921
1275 data; R1 = 0.0796
wR2 = 0.1676
R1 = 0.1539
wR2 = 0.2004
4.768 and -3.392
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Figure 31. Molecular structure of Tl(2,6-diCl-PhCO) presented using the help of mercury
program. (A) Dihedral angle, α, between the cyanoxime and the chloro-aryl group. (B) Dimeric
structure of Tl(2,6-diCl-PhCO).

Crystal structure of Tl(TCO). The crystal and refinement data for Tl(TCO) are shown
in Table 14. The ASU is presented in Figure 33. All H-atoms were attached to hosting N-atom
within the structure. Selected bond lengths and valence angles are shown in Table 15. The
cyanoxime adopts a trans-anti geometry. The molecule is planar with dihedral angle between the
mean planes for the thioamide and the cyanoxime being around 3.51 Å. The bond lengths for
N1-C1 = 1.333(6) and N1-O1 = 1.320(5) of the cyanoxime fragment are within range for the
observed bond lengths in similar complexes. Intra- and inter-molecular forces present within
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Tl(TCO) are highlighted in Figure 32. The hydrogen bond parameters are as follows; N3-H3B--O1 = 2.06 Å, H3B---O1 = 2.06 Å with the angle <DHA = 162.6 °; N3-H3A---N2 = 2.20, H3A--N2 = 2.856(6) with <DHA = 131.2 °. These H- bonds lead to the formation of sheets within the
crystal. There are also intermolecular van-der-Waal forces and electrostatic interactions that
further stabilize the crystal structure of Tl(TCO).

Figure 32. Hydrogen bonding within and between molecules of Tl(TCO) viewed along a-axis.
*Tl atom is omitted from structure for clarity.
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Table 14. Crystal and refinement data for Tl(TCO).
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

Tl(TCO)
C3 H2 N3 OSTl
332.51
100(2)
0.71073
0.164 x 0.197 x 0.231
clear light orange-yellow
monoclinic
P 1 21/c 1
a = 6.1861(5)
α = 90
b = 15.4823(12)
β = 104.7800(10)
c = 6.5276(5)
γ = 90
604.50(8)
4
3.654
26.971
584
2.63 to 25.99
-7<=h<=7
-19<=k<=19
-8<=l<=8
6788
1188 [R(int) = 0.0333]
0.0960 and 0.0620
1188 / 0 / 82
1.124
1120 data;
R1 = 0.0173
wR2 = 0.0407
R1 = 0.0185
wR2 = 0.0411
1.409 and -1.169 eÅ -3
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Figure 33. The ASU in the structure of one of the initial compounds Tl(TCO) drawn in ORTEP
representation at 50% ellipsoid probability level.

Table 15. Selected bond lengths and valence angles of the ligand Tl(TCO).
Tl(TCO)
Valence angle,o

Bond length, Å
O1 - N1

1.320(5)

C1 - N1 - O1

119.1(4)

N1 - C1

1.333(6)

C2 - C1 - N1

121.6(4)

C1 - C2

1.446(7)

N1 - C1 - C3

119.5(4)

C1 - C3

1.457(6)

C3 - C1 - C2

119.0(4)

C2 - N2

1.160(6)

N2 - C2 - C1

176.2(5)

C3 – N3

1.333(6)

N3 - C3 - S1

123.1(4)

C3 – S1

1.687(5)

N3 - C3 - C1

115.7(4)

C1 - C3 - S1

121.2(3)
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V. 4. Antimony (V) Cyanoximates
Crystal structure of SbMe3 (4-Cl-PhCO)2 . Crystal and refinement data for SbMe3 (4-ClPhCO)2 is presented in Table 16. Bond lengths and valence angles are summarized in Table 17.
Both anions within the SbMe3 (4-Cl-PhCO)2 adopt an anti-geometry (Figure 34). All the H-atoms
were calculated and placed onto hosting C-atoms for the structural solution. All methyl groups
attached to the metal Sb center were slightly different from each other in bond lengths. The bond
angle for O2-Sb1-O1 is less than 180° meaning the metal center and its bonded atoms for a
slightly distorted trigonal bipyramid geometry when compared to the initial starting compound
SbMe3 Br2 . The two anions within the molecular structure possess different planarity as shown in
Figure 35. This is mostly due to the interactions within the environment of each anion. The bond
lengths of the cyanoxime groups N1-C1 = 1.306(4) Å, N3-C9 = 1.284(4) Å, N1-O1 = 1.354(3)
Å, and N3-O2 = 1.375(3) Å are all within the expected and previously published bond lengths.
Again, differences between bond lengths for the ligand H(4-Cl-PhCO)57,83,88 and the antimony
cyanoximate can be attributed to the redistribution of the electron density in the C-N-O fragment
during the complexation to the metal Sb center. The difference in the dihedral angles within the
molecule can only be explained by the presence of bulkier atoms near cyanoxime 35A than 35B
and hence there is less steric strain present in 15B. Tl(4-Cl-PhCO) has a larger dihedral angle
than 35A and a smaller angle than 35B. The crystal structure is held together by π-π interactions
and van-der-Waal forces.
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Figure 34. Molecular structure and atomic numbering of SbMe3 (4Cl-PhCO)2 .

Figure 35. Planarity within the molecular structure of SbMe3 (4Cl-PhCO)2 . (A) anion with Cl2 and
O2; (B) anion with Cl1 and O1.
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Table 16. Crystal and refinement data for SbMe3 (4-Cl-PhCO)2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

SbMe3 (4-Cl-PhCO)2
C19 H17 Cl2 N 4O2 Sb
526.02
120(2)
0.71073
0.069 x 0.109 x 0.144
clear light colorless block
monoclinic
P 21 /n
a = 11.683(3)
α = 90
b = 7.2655(18)
β = 96.141(4)
c = 25.126(6)
γ = 90
2120.5(9)
4
1.648
1.575
1040
2.01 to 26.00
-13<=h<=14
-8<=k<=8
-30<=l<=30
17852
4135 [Rint = 0.0497]
0.8990 and 0.8050
4135 / 0 / 256
1.036
R1 = 0.0300
wR2 = 0.0642
R1 = 0.0428
wR2 = 0.0693
0.534 and -0.448

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices (all data)
Largest diff. peak/hole, eÅ -3
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Table 17. Selected bond lengths and valence angles of SbMe3 (4-Cl-PhCO)2 .
SbMe3 (4-Cl-PhCO)2
Valence angle,o

Bond length, Å
Cyanoxime:
O1 - N1

1.354(3)

C1 - N1 - O1

112.9(3)

N1 - C1

1.306(4)

C2 - C1 - N1

120.5(3)

C1 - C2

1.456(5)

N1 - C1 - C3

121.0(3)

C1 - C3

1.472(5)

C3 - C1 - C2

118.5(3)

C2 - N2

1.135(4)

N2 - C2 - C1

176.4(4)

Cl1 - C6

1.741(4)

Cl2 - C14

1.754(3)
Metal Center:

Sb1 - O1

2.093(2)

C17-Sb1-C18

120.29(15)

Sb1 - O2

2.111(2)

C18-Sb1-C19

117.01(17)

Sb1 - C17

2.087(3)

C18-Sb1-O1

95.71(12)

Sb1 - C18

2.088(3)

C17-Sb1-O2

90.43(11)

Sb1 - C19

2.092(4)

C19-Sb1-O2

91.32(12)

C17-Sb1-C19

122.69(16)

C17-Sb1-O1

91.06(12)

C19-Sb1-O1

84.29(12)

C18-Sb1-O2

87.21(11)

O1-Sb1-O2

175.49(8)

Crystal Structure of SbMe3 (2,4-diCl-PhCO)2 . The crystal and refinement data for
SbMe3 (2,4-diCl-PhCO)2 is presented in Table 18. Selected bond lengths and angles are presented
in Table 19. The molecular structure of SbMe3 (2,4-diCl-PhCO)2 can be seen in Figure 36. When
co-crystallization happens within our crystals, it is normally a combination of both diastereomers
attached to the same metal center. Here, we see a rare case of co-crystallization of two
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diastereomers within the same molecule at a 50:50 ratio. This is the first time it has been
expressed within a crystal structure. Within this complex are both trans syn and trans anti
geometry. All H-atoms were attached to the structure, not found when solved. The crystalline
specimen was a rotational twin. The bond lengths of the carbon atoms attached to the metal Sb
center are all different. The dihedral angle between the mean planes N2-C2-C1-N1-O1 and Cl2C6-C7-C8-Cl1-C3-C4-C5 is 40.83 ° for the trans anti stereoisomer which is around 10 ° smaller
than that of Tl(2,4-diCl-PhCO). This means antimony has more of a steric effect on the
cyanoxime anion than thallium. The dihedral angle for the trans syn isomer was 53.41 °. The
bond lengths for the cyanoxime group are all within the normal expected ranges for this class of
compounds. There was not a huge difference between SbMe 3 (2,4-diCl-PhCO)2 and its thallium
precursor; N1-O1 = 1.329(12), N3-O2 = 1.285(15), N1-C1 = 1.285(14), N3-C12 = 1.388(18)
compared to N1-O1 =1.294(12) and N1-C1 = 1.314(13). There are no hydrogen bonds present
and so the crystal lattice is supported by π-π stacking interactions between the aryl groups and
inter - and intra-molecular forces such as van-der-Waal forces.

Figure 36. Molecular structure and atomic numbering of SbMe3 (2,4-diCl-PhCO)2 drawn in
ORTEP at 50% ellipsoid probability level.
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Table 18. Crystal and refinement data for SbMe3 (2,4-diCl-PhCO)2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, e Å -3

SbMe3 (2,4-diCl-PhCO)2
C19 H15 Cl4 N 4O2 Sb
594.93
120.15
N/A
0.212 × 0.187 × 0.143
colorless
monoclinic
P21 /c
a = 7.1216(19)
α = 7.1216(19)
b = 23.813(6)
β = 23.813(6)
c = 13.847(4)
γ =13.847(4)
2288.4(10)
4
1.7267
1.696
1168.3
3.46 to 50.00
-8 ≤ h ≤ 8
0 ≤ k ≤ 29
0 ≤ l ≤ 17
4666
4026 [Rint = 0.0000, Rsigma = 0.1081]
0.791 and 0.984
4026/12/274
1.053
R1 = 0.0878
wR2 = 0.1629
R1 = 0.1459
wR2 = 0.1867
1.86 and -2.17
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Table 19. Selected bond lengths and valence angles of the ligand SbMe 3 (2,4-diCl-PhCO)2
SbMe3 (2,4-diCl-PhCO)2
Valence angle,o

Bond length, Å
Chloro-aryl and Cyanoxime:
O1 - N1

1.329(12)

C1 - N1 - O1

113.5(9)

N1 - C1

1.285(14)

C2 - C1 - N1

118.9(10)

C1 - C2

1.464(17)

N1 - C1 - C3

121.3(11)

C1 - C3

1.462(16)

C3 - C1 - C2

119.7(10)

C2 - N2

1.130(15)

N2 - C2 - C1

176.0(14)

N3 - C12

1.388(18)

C12 – N3 – O2

109.8(12)

N3 - O2

1.285(15)

C13 - C12 – N3

112.5(12)

N3 - C12 – C14

126.4(13)

C14 - C12 – C13

121.1(11)

N4 – C13 - C12

174.9(16)

Metal Center:
Sb1 - O1

2.100(8)

C10 - Sb1 – C9

117.4(5)

Sb1 - O2

2.184(10)

C11 - Sb1 - C9

122.4(5)

Sb1 - C9

2.079(12)

C10 - Sb1 - O1

120.2(5)

Sb1 - C10

2.065(13)

C9 - Sb1 - O1

94.0(4)

Sb1 - C11

2.099(13)

C10 - Sb1 - O1

92.2(4)

C11 - Sb1 - O1

84.9(5)

C9 - Sb1 - O2

91.1(4)

C10 - Sb1 – O2

83.9(4)

C11 - Sb1 - O2

93.8(5)

O1 - Sb1 - O2

174.6(3)

Crystal Structure of SbMe3 (2,6-diCl-PhCO)2 . The crystal and refinement data are
shown in Table 20. The molecular structure of SbMe3 (2,6-diCl-PhCO)2 is shown in Figure 37.
The cyanoxime moieties within the structure adopt an anti-geometry like their Tl precursor

74

Tl(2,6-diCl-PhCO). Selected bond lengths and valence angles are presented in Table 21. This
compound is completely non-planar. The dihedral angles between the cyanoxime group and the
disubstituted aryl group are 69.65 ° for mean planes Cl4-Ph-Cl5 and N3-C9-C10-N4, and 83.08 °
for mean planes Cl2-Ph-Cl1 and N1-C1-C2-N2. These angles are larger than the dihedral angle
in the Tl precursor which makes sense since there are bulkier atoms surrounding the cyanoxime
in SbMe3 (2,6-diCl-PhCO)2 than in Tl(2,6-diCl-PhCO)2 and hence there would be a need for more
space to minimize repulsion. The bonds in the cyanoxime group were N1-O1 = 1.359(7) Å, N3O2 = 1.354(7) Å, N1-C1 = 1.282(8) Å and N3-C9 = 1.273(8) Å. These were within the normal
expected ranges and when compared to their Tl precursor, the bond lengths do not differ much,
with any changes attributed to the redistribution of electron density due to complexation to the
metal Sb center. Slipped π-π stacking interaction is present to stabilize the crystal structure.

Figure 37. Molecular structure of SbMe3 (2,6-diCl-PhCO)2 drawn in ORTEP representation
showing the numbering scheme.
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Table 20. Crystal and refinement data for SbMe3 (2,6-diCl-PhCO)2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

SbMe3 (2,6-diCl-PhCO)2
C19 H15 Cl4 N 4O2 Sb
594.90
150(2)
0.71073
0.105 × 0.095 × 0.071
colorless
triclinic
P -1
a = 7.540(3)
α = 104.891(6)
b = 10.889(4)
β = 93.234(6)
c = 14.709(6)
γ = 100.956(6)
1138.8(8)
2
1.735
1.704
584
1.98 to 26.37°
-9≤ h≤ 9
-13≤ k≤ 13
-18≤ l≤ 18
12471
4636 [Rint = 0.0707]
0.7454 and 0.5843
4636 / 0 / 274
0.968
R1 = 0.0541
wR2 = 0.1233
R1 = 0.0847
wR2 = 0.1376
1.517 and -1.668
0.168

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Δ/ σmax
Final R indices [I>2σ(I)]
R indices (all data)
Largest diff. peak and hole, eÅ -3
R.M.S. deviation from mean, eÅ -3
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Table 21. Selected bond lengths and valence angles of the ligand SbMe 3 (2,6-diCl-PhCO)2 .
SbMe3 (2,6-diCl-PhCO)2
Valence angle,o

Bond length, Å
Chloro-aryl and Cyanoxime:
O1 - N1

1.359(7)

C1 - N1 - O1

113.1(5)

N1 - C1

1.282(8)

C2 - C1 - N1

122.2(6)

C1 - C2

1.464(9)

N1 - C1 - C3

121.2(6)

C1 - C3

1.481(9)

C3 - C1 - C2

116.5(6)

C2 - N2

1.134(9)

N2 - C2 - C1

176.3(7)

N3 - O2

1.354(7)

C9 - N3 - O2

112.7(5)

N3 - C9

1.273(8)

C11 - C9 - N3

118.0(6)

N3 - C9 - C10

123.4(6)

C11 - C9 - C10

118.6(5)

N4 - C10 - C9

177.2(8)

Metal Center:
Sb1 - O1

2.115(4)

C18 - Sb1 - O2

92.7(2)

Sb1 - O2

2.091(4)

O2 - Sb1 - C19

83.6(2)

Sb1 - C17

2.098(7)

O2 - Sb1 - C17

93.7(2)

Sb1 - C18

2.083(6)

C18 - Sb1 - O1

87.3(2)

Sb1 - C19

2.098(7)

C19 - Sb1 - O1

92.5(2)

C18 - Sb1 - C19

120.2(3)

C18 - Sb1 - C17

118.5(3)

C19 - Sb1 - C17

121.3(3)

O2 - Sb1 - O1

175.55(18)

C17 - Sb1 - O1

90.2(2)

Crystal Structure of SbMe3 (TCO)2 . The crystal and refinement data are shown in
Table 22. The crystal structure of SbMe3 (TCO)2 showing the ASU and the grow fragment of the
complex is presented in Figure 39A. Important bond lengths and valence angles have also been
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included in Figure 39B. The dihedral angle between the thioamide and the cyanoxime is 8.68°
which is larger than that of Tl(TCO) 3.51° attesting to the strain caused by the presence of
antimony and the three methyl groups. The methyl carbons reside in a special position as shown
in Figure 38, and therefore the presence of 6 hydrogens on the methyl carbons, each hydrogen
with site occupancy of 0.5. The side view shows that the complex is not planar. Intermolecular
hydrogen bonds are one of the important bonds that keep the lattice of SbMe3 (TCO)2 intact. The
parameters for the hydrogen bonds are N3-H3B---N2 = 2.19 Å, H3B---N2 = 3.016(12) Å with
<DHA = 161.8°. This bond is much weaker than that of its Tl precursor which had its hydrogen
donor-acceptor bond less than 3 Å. Electrostatic forces as well as van-der-Waal forces are
present to further stabilize the crystal structure.

Figure 38. Two orthogonal views of the structure of SbMe3 (TCO)2 .
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Figure 39. Crystal structure of SbMe3 (TCO)2 compound: A – the ASU in ORTEP representation
with atomic numbering; B – GROW fragment showing full structure with the most important bond
lengths and valence angles (H-atoms are not shown for clarity).
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Table 22. Crystal and refinement data for SbMe3 (TCO)2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

SbMe3 (TCO)2
C9 H13 N6O 2S2Sb
423.12
296(2)
0.71073
0.076 x 0.103 x 0.146
clear light yellow-bronze
orthorhombic
P 21/n
a = 14.6202(15)
α = 90
b = 16.0815(16)
β = 90
c = 7.1203(7)
γ = 90
1674.1(3)
4
1.679
1.906
832
2.53 to 25.00
-17 ≤ h ≤ 17
-19 ≤ k ≤ 19
-8 ≤ l ≤ 8
17301
1532 [R(int) = 0.0519]
0.8690 and 0.7680
1532 / 0 / 100
1.141
1139 data; R1 = 0.0645
wR2 = 0.1489
R1 = 0.0855
wR2 = 0.1618
4.515 and -1.070

Crystal Structure of SbMe3 (TDCO)2 . The crystal and refinement data for
SbMe3 (TDCO)2 is shown in Table 23. The molecular structure showing the results of co-
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crystallization during the synthesis of the complex is shown in Figure 40. Important bond lengths
and valence angles are presented in Table 24. This is the normal cases of co-crystallization we
normally see with our crystals unlike the rare case seen with the SbMe 3 (2,4-diCl-PhCO)2
mentioned earlier. In Figure 40 we see that one cyanoxime is totally in trans-syn geometry but
with the second cyanoxime, there is a co-crystallized mixture of two diastereomers: trans-syn
and trans-anti geometry. The syn-isomer is the dominant isomer with 84% while the anti-isomer
is minor with about 16%. This is confirmed by the NMR data. The geometries of the methyl
groups attached to antimony are all the same. Both acidoligands attached to the metal Sb are
non-planar and the dihedral angle for the syn-isomer is 60.76°. The co-crystallized mixture has
similar dihedral angles of 56.20° for the syn-isomer and 58.22° for the trans-isomer. The
cyanoxime bond lengths for the minor anti-isomer is much longer than the bond lengths for the
major syn-isomers. Van-der-Waal forces and electrostatic interactions are responsible for
maintaining the structural integrity of the crystal.

Figure 40. Molecular structure of SbMe3 (TDCO)2 drawn in ORTEP showing the presence of both
syn- and anti- geometrical conformations within the structure.
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Table 23. Crystal and refinement data for SbMe3 (TDCO)2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

SbMe3 (TDCO)2
C13 H21 N6O2S2 Sb
479.23
296(2)
0.71073
0.211 x 0.173 x 0.149
yellow
monoclinic
P21 /c
a = 7.540(3)
α = 104.891(6)
b = 10.889(4)
β = 93.234(6)
c = 14.709(6)
γ = 100.956(6)
2056.4(3)
4
1.548
1.562
960.0
3.118 to 52.834
-16 ≤ h ≤ 16
-15 ≤ k ≤ 14
-16 ≤ l ≤ 16
18608
4221 [Rint = 0.0590, Rsigma = 0.0542]
0.7456 and 0.6833
4221/0/231
1.031
R1 = 0.0514
wR2 = 0.1011
R1 = 0.0837
wR2 = 0.1130
1.79 and -1.25
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Table 24. Selected bond lengths and valence angles of the ligand SbMe 3 (TDCO)2 .
SbMe3 (TDCO)2
Valence angle,o

Bond length, Å
O1 - N1
N1 - C1
C1 - C2
C1 - C3
C2 - N2
S1 – C3
S2 - C8
C6 - N4a
C6 - N4
N4a - O2a
N4 - O2

Sb1 - O1
Sb1 - O2
Sb1 – O2a
Sb1 - C11
Sb1 - C12
Sb1 - C13

Cyanoxime:
1.340(6)
C1 - N1 - O1
1.306(7)
C2 - C1 - N1
1.452(9)
N1 - C1 - C3
1.488(8)
C3 - C1 - C2
1.135(8)
N2 - C2 - C1
1.663(6)
C1 - C3 - S1
1.672(7)
N3 - C3 - C1
1.55(4)
N3 - C3 - S1
1.299(9)
C4 - N3 - C5
1.37(5)
C9 - N6 - C10
1.352(9)
N5 - C7 - C6
anti - geometrical configuration:
C7 - C6 - N4a
C8 - C6 - N4a
Sb1 - O2a - N4a
syn - geometrical conformation:
C7 - C6 - N4
C8 - C6 - N4
Sb1 - O2 - N4
Metal Center:
2.114(4)
O1 - Sb1 - O2
2.163(6)
O1 - Sb1 - O2a
2.080(3)
C11 - Sb1 - C12
2.080(6)
C11 - Sb1 - C13
2.082(6)
C11 - Sb1 - O2a
2.072(6)
C11 - Sb1 - O1
C11 - Sb1 - O2
C12 - Sb1 - C13
C12 - Sb1 - O2a
C12 - Sb1 - O2
C12 - Sb1 - O1
C13 - Sb1 - O1
C13 - Sb1 - O2
C13 - Sb1 - O2a
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111.4(5)
113.3(5)
128.3(6)
117.7(5)
177.4(7)
116.4(4)
118.5(5)
125.1(5)
114.3(6)
114.2(6)
178.7(8)
148.7(16)
93.50(15)
105.0(2)
117.5(5)
134.2(6)
106.8(4)
174.2(18)
150.1(7)
120.2(3)
121.4(3)
114.7(7)
92.30(2)
83.20(2)
118.4(3)
84.90(8)
92.60(2)
92.70(2)
86.10(2)
93.20(3)
69.30(8)

Crystal Structure of SbMe3 (ACO)2 . The crystal and refinement data for this structure is
shown in Table 25. The molecular structure drawn in ORTEP can be seen in Figure 42. Selected
bond length and valence angles are presented along with the structure of SbMe 3 (ACO)2 in Figure
41. The cyanoxime moieties adopt a strictly trans-anti geometry. This compound is non-planar
with dihedral angles of 6.80° and 9.34°. The cyanoxime bond lengths are all within the expected
range for this class of compounds. Complexation of the metal Sb center with two bulkier ligands
leads to the slight distortion of the trigonal bipyramid geometry present in the starting compound
SbMe3 Br2 (Figure 43B). The amine hydrogens are responsible for the hydrogen bonding in this
structure. Figure 44 shows two views of the hydrogen bonds within SbMe3 (ACO)2 with bond
lengths for both the inter- and intra-molecular bonding present. Intermolecular electrostatic
attractions and van-der-Waal contacts help further stabilize the crystal structure of this
compound (Figure 43A).

Figure 41. Crystal structure of SbMe3 (ACO)2 with the most important bond lengths and valence
angles (H-atoms have been omitted for clarity).
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Figure 42. Molecular structure of SbMe3 (ACO)2 drawn in ORTEP showing atomic numbering.

Figure 43. Details of crystal packaging in the structure SbMe3 (ACO)2 (A) with the view of
electrostatic (red arrow) and van-der-Waals (green arrow) contacts within SbMe3 (ACO)2 units.
(B) slightly distorted trigonal bipyramidal shape adopted by the antimony core metal center.
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Table 25. Crystal and refinement data for SbMe3 (ACO)2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, eÅ -3

SbMe3 (ACO)2
C9 HN6 O4Sb
378.91
120(2)
0.71073
0.313 x 0.241 x 0.218
N/A
triclinic
P -1
a = 8.727(2)
α = 92.780(4)
b = 8.829(2)
β = 92.045(4)
c = 10.349(2)
γ = 107.665(4)
757.8(3)
2
1.660
1.840
360
1.973 to 26.430
-10 ≤ h ≤ 10
-11 ≤ k ≤ 11
-12 ≤ l ≤ 12
7575
3096 [Rint = 0.0585, Rsigma = 0.0832]
0.7465 and 0.5055
3096 / 0 / 228
0.987
2373 data; R1 = 0.0446
wR2 = 0.0791
R1 = 0.0663
wR2 = 0.0891
1.507 and -0.952
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Figure 44. Details of crystal packing in the structure of SbMe3 (ACO)2 ; two orthogonal views of
sheets formed via H – bonding.

Crystal Structure of SbMe3 (ECO)2 . The crystal and refinement data for SbMe3 (ECO)2
is shown in Table 27. The molecular structure with the numbering scheme is presented in Figure
45. The most important bond lengths and valence angles are shown in Table 28. The cyanoxime
moieties adopt a trans-anti geometry. All H-atoms within the structure were attached in APEX
and all the methyl groups around the metal Sb center are structurally and chemically equivalent.
This cyanoximate is non-planar with the methyl group attached to one of the cyanoxime moieties
coming out of the page. It forms an angle of <O6-C9-C10 = 105.1(6). This causes a dihedral
angle of 27.01 ° between the oxo fragment and the cyanoxime fragment. The second dihedral
angle is 6.05 ° for the other moiety. The bond lengths for the cyanoxime are all within the
expected range. Crystal packing within the structure consists of linear sheets, non-linearly
stacked on top of each other. Electrostatic forces and van-der-Waal forces present within the
structure maintains it lattice.
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Figure 45. Molecular structure and atomic numbering for SbMe3 (ECO)2 .
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Table 26. Crystal and refinement data for SbMe3 (ECO)2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, e Å -3

SbMe3 (ECO)2
C13 H19 N4O 6Sb
449.08
296.15
N/A
0.276 × 0.192 × 0.183
colorless
monoclinic
P21 /n
a = 9.1401(5)
α = 90
b = 16.0912(9)
β = 103.1870(10)
c = 13.4416(8)
γ = 90
1924.80(19)
4
1.5496
1.466
894.0
4.02 to 50
-12 ≤ h ≤ 12
-22 ≤ k ≤ 22
-18 ≤ l ≤ 18
29353
3375 [Rint = 0.0263, Rsigma = 0.0197]
0.7459 and 0.6738
3375/0/222
1.076
R1 = 0.0253
wR2 = 0.0654
R1 = 0.0297
wR2 = 0.0705
0.59/-0.31
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Table 27. Selected bond lengths and valence angles of SbMe3 (ECO)2.
SbMe3 (ECO)2
Valence angle,o

Bond length, Å
Cyanoxime:
O1 - N1

1.336(3)

C1 - N1 - O1

115.1(2)

N1 - C1

1.294(4)

C2 - C1 - N1

123.7(3)

C1 - C2

1.442(5)

N1 - C1 - C3

119.9(3)

C1 - C3

1.476(4)

C3 - C1 - C2

116.3(3)

C2 - N2

1.127(4)

N2 - C2 - C1

178.6(4)

N3 - O4

1.345(3)

O3 - C3 - O2

124.6(3)

N3 - C6

1.291(4)

C6 - N3 - O4

114.6(3)

C7 - C6 - N3

122.5(3)

N3 - C6 - C8

121.5(3)

C7 - C6 - C8

116.0(3)

N4 - C7 - C6

178.3(4)

O5 - C8 - O6

121.7(4)

O6 - C9 - C10

105.1(6)

Metal Center:
Sb1 - O1

2.134(2)

C12 - Sb1 - C11

120.9(2)

Sb1 - O4

2.115(2)

C13 - Sb1 - C11

120.3(18)

Sb1 - C11

2.078(3)

C13 - Sb1 - C12

118.8(18)

Sb1 - C12

2.083(3)

O1 - Sb1 - C11

90.80(12)

Sb1 - C13

2.075(4)

O1 - Sb1 - C12

91.56(12)

O1 - Sb1 - C13

87.10(12)

O4 - Sb1 - C11

91.82(12)

O4 - Sb1 - C12

91.65(12)

O4 - Sb1 - C13

86.99(13)

O4 - Sb1 - O1

174.1(8)
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Crystal Structure of SbMe3 (MCO)2 . The crystal and refinement data are shown in
Table 28. The molecular structure is shown in Figure 46. Selected bond lengths and valence
angles are shown in Table 29. The six-membered ring in the MCO-cyanoxime presents in a chair
conformation to minimize any steric hindrance. The cyanoxime adopts a trans-anti geometry and
is non-planar. The dihedral angle between the mean planes for the six-membered ring and O4N4-C8-C9-N5 is 34.11 ° compared to the mean planes involving N2-C2-C1-N1-O1 which is
59.72 °. This is mostly due to arrangements of bond around the metal Sb center and the effect it
has on the cyanoxime moieties to help alleviate steric hindrance. The bond lengths for the
cyanoxime group are all acceptable within this molecule. The crystal lattice is stabilized by π-π
stacking interactions due to the presence of the ring. Electrostatic attractions as well as van-derWaal forces further support the structure of SbMe3 (MCO)2 .

Figure 46. Molecular structure and atomic numbering for SbMe3 (MCO)2 .
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Table 28. Crystal and refinement data for SbMe3 (MCO)2 .
Parameter
Empirical formula
Formula weight, g/mol
Temperature, K
Wavelength, Å
Crystal size, mm
Color
Crystal system
Space group
Unit cell dimensions, Å, °

Unit cell volume, Å 3
Z
Density (calculated), g/cm3
Absorption coefficient, mm-1
F (000)
Θ range, °
Index ranges

Reflections collected
Independent reflections
Transmission (max and min)
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices [all data]
Largest diff. peak and hole, e Å -3

SbMe3 (MCO)2
C17 H25 N6O6Sb
531.18
120(2)
0.71073
0.201 x 0.170 x 0.050
Transparent and colorless
orthorhombic
Pbca
a = 11.3901(19)
α = 90
b = 12.602(2)
β = 90
c = 31.362(5)
γ = 90
4501.6(13)
8
1.568
1.270
2144
1.30 to 26.43
-14<=h<=14
-15<=k<=15
-39<=l<=39
52122
4621 [Rint = 0.1406]
0.7454 and 0.644
4621 / 0 / 360
1.045
3056 data; R1 = 0.0418
wR2 = 0.0930
R1 = 0.0830
wR2 = 0.1186
0.598 and -1.298
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Table 29. Selected bond lengths and valence angles of SbMe3 (MCO)2.
SbMe3 (MCO)2
Valence angle,o

Bond length, Å
O1 - N1
N1 - C1
C1 - C2
C1 - C3
C2 - N2
O4 - N4
N4 - C8

1.350(5)
1.285(7)
1.453(7)
1.494(7)
1.139(7)
1.353(5)
1.282(7)

Sb1 - O1
Sb1 - O4
Sb1 - C15
Sb1 - C16
Sb1 - C17

2.114(3)
2.123(3)
2.105(6)
2.094(5)
2.085(5)

Cyanoxime:
C1 - N1 - O1
C2 - C1 - N1
N1 - C1 - C3
C3 - C1 - C2
N2 - C2 - C1
C1 - C3 - O2
C1 - C3 - N3
O2 - C3 - N3
O4 - N4 - C8
N4 - C8 - C9
N4 - C8 - C10
C9 - C8 - C10
N5 - C9 - C8
C8 - C10 - O5
C8 - C10 - N6
N6 - C10 - O5
Metal Center:
C17 - Sb1 - C16
C17 - Sb1 - C15
C16 - Sb1 - C15
C17 - Sb1 - O1
C16 - Sb1 - O1
C15 - Sb1 - O1
C17 - Sb1 - O4
C16 - Sb1 - O4
C15 - Sb1 - O4
O1 - Sb1 - O4

93

114.2(4)
120.8(5)
122.2(5)
116.0(5)
178.5(6)
116.7(5)
119.6(5)
123.6(5)
114.8(4)
123.1(5)
122.0(5)
114.5(5)
179.0(6)
116.7(5)
120.2(5)
123.0(5)
120.5(2)
120.1(2)
119.4(3)
90.04(17)
93.21(19)
85.20(2)
88.64(17)
90.83(19)
92.10(2)
175.9(13)

V. 5. Differential Scanning Calorimetry - Thermal Gravimetric Analysis (DSC/TGA)
Thermal analysis of solids provides important information about samples’
thermodynamic stability. In case of investigations of biologically active compounds, it is critical
to know whether they are stable at temperatures above 105 °C normally used for sterilization
purposes. The most accurate way of investigating the thermal stability of new compounds is via
the Thermogravimetry/ Differential Thermal Analysis (TG/DTA) method. TG/DTA measures
temperatures where decomposition, reduction or oxidation occurs within a sample. This method
simultaneously measures the weight changes associated with all these physical or chemical
changes happening, as well as phase changes that indicate melting within the sample.
Traces of samples’ weight loss and heat flow were recorded with the help of Q-600
TG/DSC analyzer from TA Instruments (Delaware, USA) in the range of 30 – 800 °C. The UHP
grade argon was used as gas carrier at 100±1 mL/min flow rate and 10°/min heating rate. The
brand-new alumina crucible was calcined prior to experiment using the propane torch. Data were
processed and graphed using the TA Universal Analysis software package and allowed accurate
determination of the melting point of a target cyanoxime. The thermogram of SbMe 3 (ECO)2 as a
representative example is shown in Figure 47. The melting point was found to be 140.52 °C and
decomposition started at X. The melting points for all the synthesized antimony (V)
cyanoximates have melting points above 100 ° and decompose well beyond that. This makes it
possible for use in drug development or in medical devices which aligns with our goals for this
research. Additional thermograms can be found in Appendix B. All studied Sb(V) cyanoximates
were found to be stable to ̴ 120 – 140 °C, which clears their application as potential active
pharmaceutical ingredients (APIs).
Digimelt was used to measure the melting point of compounds that the TG/DSC analyzer
could not accurately measure. Moreover, these measurements were carried out in open air.
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Figure 47. Thermal analysis traces for SbMe3 (ECO)2 : panoramic view. Melting point at 140.52 °
and decomposition ̴ 170°C. Green line indicates the weight loss and blue line indicates heat flow.
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V. 6. NMR Spectroscopy
The NMR spectra for all the compounds were recorded at room temperature by Dr.
Sergiy Tyukhtenko from NEU in Boston, MA using the Varian INova-400 MHz. All the
assignments of chemical shifts were made based off previous work completed by Dr.
Gerasimchuk and his research group. Due to low quantities and other technical difficulties with
the synthesized compounds, NMR spectra were not obtained for all the newly synthesized
compounds. A typical example of the spectral appearance of one of the organic ligands, synH(2,6-diCl-PhCO) is shown in Figure 48 and 49. A bulk sample of synthesized dichlorosubstituted arylcyanoxime H(2,6-diCl-PhCO) demonstrates the presence of both syn- and antiisomers in solutions. Thus, the 13 C{1 H} NMR spectrum of protonated arylcyanoximes HL in
dmso-d 6 solutions contains a double set of signals (Figure 49). The exact assignment of the NMR
signals of the individual isomers within the mixture was accomplished using HMQC and HSQC
techniques. The proton NMR spectra {1 H} of the arylcyanoximes — which represent an isomeric
mixture in dry dmso-d 6 and acetone-d 6 — show the presence of two broadened signals of the NOH group at ~14ppm at room temperature (Figure 48). Heating the dmso-d 6 solutions of this
cyanoxime to +105°C did not lead to changes in the 13 C{1 H} NMR spectrum. Thus, there is no
interconversion of isomers in the mixture:
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The crystal data of some synthesized Sb(V) cyanoximates also evidenced co-crystallization of
two diastereomers which were confirmed by 13 C{1 H} NMR spectroscopy. Thus, SbMe3 (TDCO)2
contained co-crystallized mixture of two isomers shown in its NMR spectra. The 13 C{1 H}
spectra for Tl(TDCO) and SbMe3 (TDCO)2 are presented in Figures 50 and 51 respectively as
typical examples of spectral appearance of the mixture. In Figure 50A, the 1 H presents three
separate hydrogen environments when there should only be two corresponding to the methyl
groups in both the syn- and anti- isomer. This is caused by the charge distribution between the
elements S=C-N(Me)2 within the molecule. Consequently, each isomer should have two different
hydrogen environments for the methyl hydrogens, but due to an accidental overlap, only three
absorbance signals are seen in the 1 H spectra. Confirmation of this explanation is found in the
integrations of each absorbance signal. The most downfield signal has an integration of about 6
compared to about 3 for the other upfield signals. The

13 C{ 1 H} in Figure

50B further shows the

presence of two diastereomers within Tl(TDCO) with a double set of absorbance signals. In
Figure 51, the 13 C{1 H} showed the presence of two diastereomers at uneven ratios within the
structure of SbMe3 (TDCO)2. Coupled with x-ray crystallography, we determined that the syn isomer was more dominant than the anti- isomer, with the syn- isomer having an 84% occurrence
compared to 16% for the anti- isomer.
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Figure 48. The 1 H NMR spectrum of the H(2,6-diCl-PhCO) in DMSO-d 6 at RT showing presence
of two diastereomers clearly seen in the oxime-group range.
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Figure 49. The 13 C{1 H} NMR spectrum of the H(2,6-diCl-PhCO) in DMSO-d 6 at RT showing
presence of two diastereomers.
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In summary, the use of NMR spectroscopy was crucial in the confirmation of the correctness in
assignments of the presence of two diastereomers of cyanoximes in studied compounds, and that
these findings were not just crystallographic disorders.

Figure 50. The RT NMR data for Tl(TDCO) in dmso-d 6 showing presence of two diastereomers:
A – 1 H spectrum in which there is accidental overlap of two methyl groups (indicated with *); B
– 13 C spectrum in the sp2 carbon atoms region.
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Figure 51. The 13 C{1 H} NMR spectrum of SbMe3 (TDCO)2 in dmso-d 6 at RT showing presence
of two diastereomers.

V. 7. Antimicrobial Studies
The biological activity studies were performed by our collaborators at Oklahoma State
University in the Department of Microbiology and Molecular Genetics. These collaborators are
Dr. Marianna Patrauchan and her research group (antibacterial studies), and Dr. Karen Wozniak
and her research group (antifungal studies). Due to limited quantity of synthesized compounds
and other technical difficulties, the biological activity data was obtained only for some of my
synthesized compounds, and they will be described below. The rest of the compound sent for
testing will be summarized later.
Minimum Inhibition Concentration (MIC) Tests. Minimum Inhibition Concentration
(MIC) assays determine the lowest concentration of an antimicrobial agent that prevents the
visible growth of a microorganism.92 A dilution gradient of the synthesized compound is made
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and tested against microbial strains. The cell growth at each concentration is measured to show
the effectiveness of the compound. A total of nine newly synthesized compounds were
submitted to OSU for biological testing. SbMe3 Br2 and the cyanoxime ligands accompanied
these compounds to OSU for biological activity testing. For these tests, the compounds had to be
dissolved in DMSO. DMSO has inhibition effects at concentrations of 200 µg/mL and so that
was taken into consideration when determining the effects of my newly synthesized compounds
on bacteria and fungi. Antibacterial activity was assessed by testing my synthesized compounds
against P. aeruginosa, E. coli, and S. aureus. The control used in all the testing was my initial
compound SbMe3 Br2 . Unbound, free cyanoximes, HL, were also used as controls to see if there
were any synergistic effect when Sb(V) source was combined with the cyanoxime. The
independent variable was the concentrations of the compounds used in the MIC tests and the
dependent variable was cell growth measured.
MIC Tests for the Most Effective Compounds. The SbMe3 (MCO)2 was the most
effective compound against P. aeruginosa. At ̴ 50 µg/mL, there was barely any cell growth and
at subsequent concentrations afterwards indicating significant antimicrobial effect. Its ligand,
H(MCO) that is in the structure, did not have the same effect when tested against the same
bacterial strain. Figure 52 shows the comparison between the effects of the SbMe 3 Br2 (which
was our control substance), H(MCO), and SbMe3 (MCO)2 on P. aeruginosa. The control also had
significant activity at ̴ 50 µg/mL but was less than that of SbMe3 (MCO)2 . All the other tested
compounds on this strain on bacteria were not significantly effective. My compounds were also
tested against E. coli and the cell growth analysis showed that SbMe3 (2,6-diCl-PhCO)2 was the
most effective compound at stopping the growth of E. coli at a concentration of ̴ 50 µg/mL, like
SbMe3 (MCO)2 on P. aeruginosa. Figure 53 shows results of the MIC tests against E. coli where
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SbMe3 (2,6-diCl-PhCO)2 was more effective than the control used. My antimony cyanoximates
were not very effective against MRSA, with only the control being the compound that was able
to completely stop bacterial cell growth at ̴ 100 µg/mL, with significant effect being seen at ̴ 50
µg/mL. Only the control and the ligand H(2,4-diCl-PhCO) were effective against the S. aureus
(MRSA) strain used in the biological testing. Significant MRSA cell growth inhibition was seen
at ̴ 100 µg/mL for H(2,4-diCl-PhCO), with no cell growth recorded at ̴ 150 µg/mL (Figure 54).
MIC Tests for Remaining Compounds. The graphical results for the MIC tests of
compounds that were not very effective against the strains of bacteria they were tested on will be
presented in this section. The MIC results for P. aeruginosa are shown in Figures 55 to 60.
Figures 61 to 65 illustrate the MIC results for compounds tested against E. coli, and Figure 66
shows the results acquired from testing the free cyanoxime, H(2Cl-PhCO), and SbMe3 (2ClPhCO)2 against MRSA. Some of these graphs do not include the MIC test result for the free
cyanoxime, which will be presented later. My research goals included assessing the effectiveness
of my synthesized compounds against the most effective compounds in Kevin Pinks’ research
work. On comparison of the controls, (SbMe3 Br2 vs SbPh4 Br), Figure 67 shows that SbMe3 Br2
was more effective at inhibiting bacterial growth its bulkier counterpart, SbPh 4 Br. The SbMe3 Br2
had the lower MIC average of the two showing that a lower concentration of SbMe 3 Br2 is needed
to inhibit bacterial cell growth. Lastly, Table 30 and 31 summarizes the effectiveness of each
compound against the bacterial strains it was tested against. It shows the MIC (µg/mL) for an
easier understanding of the results achieved in this research project.
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Cell growth of P. aeruginosa
Cell growth (OD600)
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Concentration (ug/ml)
SbMe3Br2

H(MCO)

SbMe3(MCO)2

Figure 52. Results of MIC tests of SbMe3 Br2 , H(MCO) and SbMe3 (MCO)2 against P. aeruginosa.
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Cell growth of E. coli
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Figure 53. Results of MIC tests of SbMe3 Br2 , and SbMe3 (2,6-diCl-PhCO)2 against E. coli.
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Figure 54. Results of H(2,4-diCl-PhCO) testing against MRSA, compared to SbMe3 Br2 showing
a downward trend for the free cyanoxime from 25 µg/mL to complete inhibition at 150 µg/mL.
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Figure 55. Results of MIC tests of SbMe3 Br2 , H(2-Cl-PhCO) and SbMe3 (2-Cl-PhCO)2 against P.
aeruginosa.
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Figure 56. Results of MIC tests of SbMe3 Br2 , H(ECO) and SbMe3 (ECO)2 against P. aeruginosa.
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Figure 57. Results of MIC tests of SbMe3 Br2 , H(2,4-diCl-PhCO) and SbMe3 (2,4-diCl-PhCO)2
against P. aeruginosa.
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Figure 58. Results of MIC tests of SbMe3 Br2 , and SbMe3 (TDCO)2 against P. aeruginosa.
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Figure 59. Results of MIC tests of SbMe3 Br2 , and SbMe3 (2,6-diCl-PhCO)2 against P. aeruginosa.
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Figure 60. Results of MIC tests of SbMe3 Br2 , and SbMe3 (TCO)2 against P. aeruginosa.
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Figure 61. Results of MIC tests of SbMe3 Br2 , H(ECO) and SbMe3 (ECO)2 against E. coli.
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Figure 62. Results of MIC tests of SbMe3 Br2 , H(2-ClPhCO) and SbMe3 (2-ClPhCO)2 against E.
coli.
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Figure 63. Results of MIC tests of SbMe3 Br2 , H(2,4-diCl-PhCO) and SbMe3 (2,4-diCl-PhCO)2
against E. coli.
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Figure 64. Results of MIC tests of SbMe3 Br2 , and SbMe3 (TDCO)2 against E. coli.
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Figure 65. Results of MIC tests of SbMe3 Br2 , and SbMe3 (TCO)2 against E. coli.
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Figure 66. Results of MIC tests of SbMe3 Br2 , H(2-ClPhCO) and SbMe3 (2-ClPhCO)2 against
MRSA.
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Figure 67. Comparison of the average MIC for both SbMe3 Br2 and SbPh4 Br against E. coli and
P. aeruginosa.
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Table 30. Summary of average MIC (g/mL) result from biological activity tests.

Organism

Clinical

SbMe3 Br2

Significance

(control)

MCO

ECO

TCO

TDCO

HMCO

SbMe3
(MCO)2

HECO

SbMe3
(ECO)2

HTCO

SbMe3
(TCO)2

HTDCO

SbMe3
(TDCO)2

P. aeruginosa
(PAO1)

Lab-adapted
strain
isolated from
burn wound

100

>200

100

>200

>200

N/A

>200

N/A

>200

E. coli
(S17 (O113:H4))

Avian
Pathogenic

150

N/A

N/A

>200

>200

N/A

>200

N/A

>200

S. aureus
(NRS70)

MRSA

100

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A
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Table 31 Contd. Summary of average MIC (g/mL) result from biological activity tests.

Organism

Clinical
Significance

SbMe3 Br2
(control)

2Cl-PhCO

H(2ClPhCO)

SbMe3
(2ClPhCO)2

2,4-diCl-PhCO

SbMe3
H(2,4-diCl(2,4-diClPhCO)
PhCO)2

2,6-diCl-PhCO

H(2,6-diClPhCO)

SbMe3
(2,6-diClPhCO)2

P. aeruginosa
(PAO1)

Lab-adapted strain
isolated from burn
wound

100

>200

>200

>200

>200

N/A

>200

E. coli
(S17 (O113:H4))

Avian Pathogenic

150

>200

>200

>200

>200

N/A

100

S. aureus
(NRS70)

MRSA

100

>200

>200

150

N/A

N/A

N/A
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VI. CONCLUSION AND SUMMARY

The results and accomplishments made with this research project are summarized and outlined
below.
1. A total of 18 compounds were synthesized in this research project: Trimethylantimony
dibromide, 4 arylcyanoxime ligands, 4 thallium arylcyanoximates, and 9 methylantimony (V) cyanoximates.
2. Other precursors used such as Ag(I) cyanoximates, Tl(TCO) and Tl(TDCO) were
previously synthesized by Dr. Gerasimchuk and his research laboratory.
3. These synthesized methyl - antimony (V) cyanoximates and their precursors were
characterized using x-ray crystallography, IR, NMR and TG/DSC analysis. Crystal
structures were determined for all synthesized compounds.
4. These structural characterizations of the methyl-antimony (V) cyanoximates are the first
structural characterizations to be ever done in this field.
5. All the methyl-antimony (V) cyanoximates adopt a distorted trigonal bipyramid
conformation around the core antimony metal center.
6. Some peculiarities and rare findings in my research include.
o A rare case of pure syn- diastereomer of H(2,6-diCl-PhCO) being isolated and
studied. Previously, mixtures of the two diastereomers was obtained and the pure
anti- isomer was not characterized.
o Sulfur- hydrogen bonding present in the structure of the ligand HTDCO to
stabilize its crystal structure.
o Co-crystallized mixture of dominant syn-isomer (84%) and minor anti- isomer
(16%) within the structure of SbMe3 (TDCO)2 .
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o 50:50 co-crystallized mixture of both syn- and anti-diastereomers in SbMe3 (2,4diCl-PhCO)2 . This is a new occurrence as there is always a dominant
diastereomer within these mixtures like SbMe3 (TDCO)2 .
7. 8 of the synthesized methyl - antimony cyanoximates and their corresponding ligands
were sent to OSU for biological studies including the trimethylantimony dibromide.
8. Minimum Inhibition Concentration tests were run with the synthesized cyanoximates
against three different strains of bacteria: Pseudomonas aeruginosa PAO1, Escherichia
coli S17, and Methicillin- resistant Staphylococcus aureus NRS70. The highest
concentration tested was 200 g/mL. The results are as follows.
o SbMe3 (MCO)2 was significantly effective against PAO1 at concentrations
between 25 g/mL and 50 g/mL. Complete inhibition observed between 50
g/mL and 100 g/mL.
o SbMe3 (2,6-diCl-PhCO)2 was significantly effective against E. coli at
concentrations between 25 g/mL and 50 g/mL. Complete inhibition observed
between 50 g/mL and 100 g/mL.
o The ligand H(2,4-diCl-PhCO) was the only compound effective against MRSA.
MRSA cell growth decline was observed at 50 g/mL and complete inhibition
was seen at 150 g/mL.
9. Further tests must be conducted to be able to compare my results with that of my
colleague Kevin Pinks. The initial compound used in my research, SbMe 3 Br2 was more
effective against all the bacterial strains than SbPh 4 Br, used by Kevin Pink.
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